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Dental polymer-based materials have become the first choice for restorative treatment 
in many countries, and the increased use of these materials over the last decades has 
raised questions about their biological safety. It has been shown that monomers as 
well as contaminants can leak from dental polymer-based restorations. Due to its 
estrogenic effect, bisphenol A (BPA) has been considered as a compound of specific 
interest. Exposure to BPA during early developmental stages of life is of particular 
concern. Large epidemiological studies exploring whether placement of dental 
polymer-based restorative materials in pregnant women is associated with increased 
risk for the fetus are warranted. 
The overall aim of the present work was to gain knowledge about the exposure to 
BPA from dental polymer-based restorations in humans and to investigate whether 
placement of polymer-based dental fillings during pregnancy is associated with 
increased risk for adverse birth outcomes. 
The thesis comprises three studies. In the first study, 20 individuals with six or more 
tooth surfaces filled with polymer-based materials (composite group) and 20 
individuals without dental polymer-based materials (comparison group) were 
enrolled. Saliva was collected to assess if presence of dental polymer-based fillings is 
associated with increased salivary BPA level. In the second study, 20 patients who 
were scheduled for treatment of at least two tooth surfaces with dental polymer-based 
restorative material were included. Saliva and urine were collected before and up to 
one week after treatment to assess if placement of dental polymer-based material is 
associated with increased BPA concentrations in saliva and urine. The BPA 
concentration in the biological samples was determined using liquid 
chromatography/mass spectrometry. Presence of dental polymer-based fillings was 
associated with slightly higher concentration of BPA in saliva. Directly after 
treatment with dental polymer-based material, there was a considerable increase in 
the concentration of BPA in saliva. After the initial increase, the concentration 
14 
decreased exponentially over time. One week after treatment, the salivary BPA level 
was only marginally higher compared to the pretreatment level. In urine, no 
statistically significant change of BPA concentration after placement was observed.  
In the third study, data from the large Norwegian Mother and Child Cohort Study was 
used to investigate if placement of white fillings during pregnancy was associated 
with increased risk for adverse birth outcomes. The results indicated that there was no 
statistically significant increased risk for adverse birth outcomes for participants who 
had white fillings placed during pregnancy compared with women who did not 
consult a dentist during pregnancy. 
In conclusion, dental polymer-based restorative materials might contribute to BPA 
exposure in humans. However, the exposure appears to be relatively short and 
transient. Women participating in the Norwegian Mother and Child Cohort Study 
who received dental polymer-based restorations (white fillings) during pregnancy had 
no increased risk for adverse birth outcomes including stillbirth, malformations, 
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Today tooth-colored dental polymer-based materials are available for various clinical 
applications and have become the first choice for restorative treatment in several 
countries (1). The focus on minimally invasive and aesthetic dentistry, as well as the 
decision for a global phase-down of amalgam (2) have likely contributed to this trend. 
The term dental polymer-based restorative material generally refers to a reinforced 
polymer (resin) matrix used to replace or restore missing portions of tooth structure 
directly on the tooth (3, 4). The increased use of these materials in recent decades has 
raised questions about their safety and biocompatibility. The materials are not inert in 
the oral environment, and they release components with potential adverse effects (5). 
Over the years, dental polymer-based restorative materials, also known as resin-based 
restorative materials, dental composites, or tooth-colored filling materials, have been 
subject to continuous and extensive research in an effort to improve their mechanical 
properties, their bonding to the tooth structure, and their biocompatibility.  
Major improvements in clinical performance of tooth-colored dental materials took 
place in the late 1950s and early 1960s (6). In 1955, Buonocore introduced the acid-
etch technique as a method to increase the adhesion of the polymeric material to 
enamel (7). In the early 1960s, silica powder was combined with bisphenol A 
glycidylmethacrylate (bis-GMA, also called “Bowen’s resin”), and this new product 
exhibited increased strength, increased hardness, and decreased polymerization 
shrinkage compared to the previous resin-based materials (8, 9).  
 
 
Dental polymer-based restorative materials in use today generally consist of different 
types of inorganic filler particles embedded in an organic polymer-based matrix (4, 




polymerization are cross-linked to create a rigid polymer network. Furthermore, the 
matrix also consists of photo initiators and other additives (4, 10).  
Legal aspects 
Because the main intended function of dental materials is to replace lost tissue, these 
materials are defined as medical devices (11). In the European Union they have to 
meet general requirements of the European Medical Devices Regulation 
(MDR/2017/745) in order to obtain the CE marking (12) that is mandatory for the 
product to be marketed in the European Economic Area (including Norway). By CE 
marking, the manufacturer demonstrates that the product is in compliance with the 
essential requirements (e.g. “Requirements regarding design and manufacture”) of the 
MDR and other applicable directives from the European Commission (EC directives). 
According to the MDR, medical devices should not compromise the safety of patients 
or operators (11). Potential hazardous constituents should be labeled and supplied 
with an information sheet (e.g. safety data sheets) (13). The MDR does not describe 
in detail how the requirements have to be fulfilled. One possibility is compliance with 
appropriate standards, such as those of the International Organization for 
Standardization (ISO). Currently, for dental polymer-based restorative materials, ISO 
4049-2019 is the standard that specifies the requirements 
(https://www.iso.org/standard/67596.html). However, even if standards are used, the 





The main ingredients in the organic matrix are most commonly a blend of aromatic 
and aliphatic dimethacrylate monomers with two reactive groups (Figure 1). The 
matrix monomers are fluids with different viscosities and molecular weights. The 




used in combination with or instead of bis-GMA include urethane dimethacrylate 
(UDMA) and bisphenol A dimethacrylate (bis-DMA). To reduce the viscosity and 
obtain optimal clinical consistency of the material, low molecular-weight co-
monomers, for example, triethyleneglycol dimethacrylate (TEGDMA) or bisphenol A 
ethoxylate dimethacrylate (bis-EMA), are added as diluents by the manufactures (4, 
15). In order to simplify the application procedures, attempts have been made to use a 
variety of other matrix monomers over the years (16). Moreover, materials relying on 
silorane and ormocer (organically modified ceramic) technologies have also been 








Figure 1. Structures of the monomers bis-GMA, bis-EMA, bis-DMA, TEGDMA, and 
UDMA. 
 
Initiators and inhibitors/stabilizers 
To promote the polymerization reaction, initiators are added to the matrix. In most 
materials, the polymerization is activated by light (18). Camphorquinone (CQ) is a 
commonly used photo initiator and absorbs light with wavelength from 400–500 nm 




incorporated in the catalyst paste and an organic peroxide is incorporated in the 
universal paste. The polymerization starts as soon as the catalyst paste and the 
universal paste are mixed. Dual-cured materials use a combination of chemical and 
light activation and contain initiators and accelerators that allow light activation 
followed by self-curing. To prevent premature activation of the polymerization, and 
thereby extend the materials’ storage life and to ensure sufficient working time, 
inhibitors or stabilizers are added (4). Components that can enhance color stability 
are additional ingredients (4). 
 
 
To improve the physical and mechanical properties of the polymer-based materials, 
different sizes and types of filler particles are incorporated in the polymer matrix. 
Traditionally these particles have been minerals such as quartz, glass, or ceramic, as 
well as organic pre-polymerized resin particles. Benefits of the fillers include 
reinforcement of the polymer matrix, increased wear resistance, reduction of the 
volume shrinkage and thermal expansion, and optimization of the workability as well 
as imparting radiopacity and a degree of translucency. Polymer-based restorative 
materials are generally classified based on the size of the particles, namely macro-




The filler particles are coated with coupling agents (e.g. silane) that have reactive 
groups that can ensure a strong bond between the filler particles and the polymer 






Figure 2. Schematic illustration of filler particles coated with a coupling agent (silane) and 
embedded in a polymer-based matrix. Inspiration for the figure (18, 19).  
 
 
To bond the polymer-based restorative material to the tooth substance, an adhesive 
system is needed. Although enamel and dentin differ in structure and composition, 
resin-based systems available today can bond to both the enamel and dentin of the 
tooth. The systems are classified according to the etching strategy, such as total etch 
(etch-and-rinse) or self-etch (20). Total etch require a separate acid step to etch the 
enamel and dentin, a subsequent rinse, and application of primer and adhesive. 
Phosphoric acid gel (30–40%) is used to demineralize the tooth structure. Total etch 
can be presented as a three or two-step system depending on whether primer and 
adhesive are separate or combined in a single bottle. In self-etch systems, acidic 
monomers etch and prime the tooth simultaneously before application of the adhesive 
(two-step). Self-etch systems are also available as a one-step alternative with the 









a) Source: European Chemical Agency, https://echa.europa.eu/. Info Card data generated 
from information based on industry data. R – Toxic to reproduction; Ss – Skin sensitizer; 
Updated June 05, 2019. 






Originally, dental composites were two-component and the polymerization was 
chemically activated. However, during the 1970s light curing and more operator- 
friendly materials became available. Today, visible blue-light-activated materials 
with increased depth of cure, controllable working time, and other advantages are 
available (10).   
Dimethacrylate monomers undergo free radical addition polymerization by opening 
the carbon double bonds and forming single bonds (Figure 3). During this process, 
which requires a source of free radicals to be initiated, most of the monomers are 
converted into polymers and cross-linked to form a three-dimensional network 
system.  
 
Figure 3. Schematic illustration of the polymerization of methacrylates and resulting 
volumetric shrinkage. Figure modified from (4). 
 
Highly viscous monomers (e.g. bis-GMA) and crosslinking of polymer chains reduce 
the monomers’ ability to move and hence, to participate efficiently in the 
polymerization within the bulk of the material. Thus, the conversion of monomers to 
polymers, either chemical or light initiated, is never complete (22-24). The degree of 
conversion, defined as the percentage of carbon double bonds that converts into 
single bonds during polymerization, might vary between 50% and 70% (10). Most of 
the monomers will polymerize and have at least one of their reactive methacrylate 




completely unreacted monomers (residual monomers) that can migrate out of the 
network (24) (Figure 4).  
 
Figure 4. Polymer network and dimethacrylate groups with zero, one, or two unreacted 
double bond. Completely unreacted monomers (residual monomer) can migrate out of the 
polymerized material. Figure modified from (10). 
 
The extent to which monomers are converted might be influenced by several factors 
including the composition of the polymer-based material, the curing time, the light 
intensity, the distance to the light curing tip, and the thickness of the incremental 
layer (25). Oxygen reacts rapidly with free radicals and thus inhibits the 
polymerization reaction on the matrix surface (the oxygen-inhibited layer) (26). Thus, 
on the free (exposed) surfaces of the dental polymer-based restorations the degree of 
conversion might decrease up to 20% resulting in higher amounts of potentially 






Results from numerous in vitro and in vivo studies have shown that unpolymerized 
monomers, additives, and filler components might leak from dental polymer-based 
materials (5, 28-31). In addition, impurities from the production process and 
degradation products formed during and after curing might be present in the 
polymerized material and might migrate out of the material (32, 33). 
In the oral cavity, the leakage might initially be due to the incomplete polymerization 
on the surfaces and later to mechanical, enzymatic, and hydrolytic degradation of the 
material (27, 34-37). Aging and wear of the materials might result in porosities 
leading to increased release of residual monomers originally trapped in the polymer 
network.  
Substances released from polymer-based restorations might reach the biological 
environment by diffusion through the pulp via dentinal tubuli, directly through the 
oral mucosa, by absorption via volatile components in the lungs and by ingestion of 
released substances in the gastrointestinal tract (27).  
 
 
Studies have shown that dental polymer-based materials and their constituents 
potentially have allergic (38, 39), cytotoxic (40-42), genotoxic (42), or estrogenic 
effects (43, 44). The potential release and estrogenic effect of bisphenol A (BPA), has 







Bisphenol A (Cas nr: 80-05-7) is a white, solid organic synthetic compound prepared 
by the combination of two equivalents of phenol with one equivalent of acetone 





Figure 5. Synthesis of BPA from two phenol molecules and one acetone molecule in the 
presence of a catalyst (e.g. hydrogen chloride). Figure adapted from 
(https://commons.wikimedia.org/wiki/).  
 
Table 2. Substance identifications and physico-chemical characteristics of BPA (46).  
 
Chemical name Bisphenol A (BPA) 
Physical state at normal White solid flakes or powder 
CAS number 80-05-7 
Formula C15H16O2 
Molecular weight 228.29 g/mol 
Melting point ~160 °C 
Solubility in water ~300 mg/l (low) 
 
BPA was first reported as a synthetic chemical in the 1890s by the Russian chemist 
Alexander P. Dianin (47). During the 1930s, when there was a global scientific effort 
to develop pharmaceutical estrogens, BPA was identified to have estrogenic 




BPA was temporarily dismissed (49). BPA’s commercial value was reassessed during 
the 1950s when chemists discovered BPA as a very valuable chemical in the plastics 
industry. Since then BPA has been widely used in commercial production.  
Today, BPA is a high-volume production chemical, mainly used in the manufacture 
of polycarbonate plastics and epoxy resins. Based on data from the European 
Chemical Agency, 1–10 million tons of BPA is manufactured and/or imported in the 
European Economic Area every year (50). Polycarbonate plastics are used in 
numerous everyday items such as food and beverage containers, plastic tableware, 
children’s toys, mobile phones, and many other consumer products. Epoxy resins are 
often used inside metal cans as protective linings. BPA might also be present in 
thermal paper, medical devices, and a wide range of other products (51). Given the 
large amount of BPA containing products, exposure to BPA in developed countries is 
ubiquitous (52).  
 
 
In humans, the major BPA exposure is assumed to be through the diet. BPA can 
migrate in small amounts into food and beverages stored in materials made of 
polycarbonate or in cans coated with epoxy linings (51, 53, 54). However, BPA 
levels in human matrices (e.g. urine) cannot be explained by dietary exposure alone 
(54, 55). Non-dietary sources and pathways have received increased attention, and 
recent studies have indicated human exposure also from several non-dietary sources 
such as dust and indoor air, thermal paper, cosmetics, and medical devices including 






BPA is not intentionally added to dental polymer-based materials. However, it is a 
raw material in the synthesis of several of the widely used methacrylate monomers 




Figure 6. Synthesis of bis-GMA from BPA and glycidyl methacrylate. 
 
Human saliva contains enzymes (e.g. proteases and esterases) that might have an 
impact on dental materials and the released compounds (34). In 1996, Olea et al. 
conducted the first in vivo study examining released components after placement of a 
dental sealant and detected BPA in saliva within 24 hours after placement of a bis-
DMA-based sealant (44). Studies have shown that there is a considerable conversion 
of bis-DMA to BPA due to hydrolysis at the ester bond (-O-CO-) (59-61). However, 
BPA derivatives with an ether bond (-O-), such as bis-GMA and bis-EMA, do not 







Figure 7. Hydrolysis of bis-DMA into BPA at the ester linkage. Bis-GMA does not 




BPA can enter the human body via different routes. The major route is considered to 
be through the gastrointestinal tract after ingestion (54). After investigating 
anesthetized dogs, Gayrard et al. suggested that BPA exposure could occur through 
the oral mucosa (sublingual), leading to detectable levels of unconjugated BPA in the 
blood (63). In contrast, Teeguarden et al. reported evidence against sublingual BPA 
absorption in humans ingesting soup containing deuterated BPA (D6-BPA) (64). 
Toxicokinetic studies have indicated that BPA can enter the body through the skin 
(e.g. via contact with cosmetics or thermal paper) or through the respiratory mucosa 
via dust (54, 65, 66) (Figure 8). In addition, other parenteral exposure routes, such as 
subcutaneous and intravenous routes (e.g. relevant for medical devices), might be 






Figure 8. Illustration of different routes of exposure to BPA. Inspiration for the figure (56).  
 
The estrogenicity of BPA in humans is dependent on the routes of exposure. Ingested 
BPA is rapidly absorbed in the gastrointestinal tract and inactivated through the first-
pass metabolism in the gut wall and in the liver (67-69). In this metabolic process, 
most of the BPA is converted from a bioactive, estrogenic form (unconjugated/free 
BPA) via enzyme activity to water-soluble non-estrogenic forms (conjugated BPA). 
The conjugated metabolites, mainly BPA glucuronide and, to a lesser extent, BPA 
sulfate, have no estrogen receptor affinity and are therefore of less toxicological 







Figure 9. Schematic illustration of BPA glucuronidation in the gut and liver and routes of 
elimination of BPA conjugates in humans and rodents. Inspiration for the figure (47, 72, 73).  
 
In contrast, if BPA enters the body via the parenteral routes (e.g. dermal or inhalation 
routes), results from animal studies have concluded that the absorbed BPA enters the 
systemic circulation before it is metabolized in the liver (74-76). Hence, 
unconjugated BPA (the bioactive form) might circulate in the body for a longer 
period of time.   
In rodents (i.e. rats and mice) BPA is also mainly glucuronidated, although it is 
suggested that the BPA glucuronide can be deconjugated in the gut and be re-
circulated back to the liver (“enterohepatic recirculation”) resulting in slower 
elimination of BPA (Figure 9) (75). Thus, ingestion of an equivalent BPA dose might 
result in higher blood levels of unconjugated BPA in rodents compared to humans. 
Pharmacokinetics studies using controlled doses of isotopically labeled BPA suggest 
that following oral administration in adult humans, 84–97% of ingested BPA is 
absorbed and excreted as BPA or BPA conjugates in urine within 5–7 hours (64, 73, 
77). This is consistent with a short elimination half-life of BPA in urine of 
approximately 2 hours (64). After 24 hours, recovery from urine is almost complete 





Endocrine-disrupting chemical  
BPA is now well known to be an endocrine-disrupting chemical, with the ability to 
interfere with and mimic estrogenic hormones (78, 79). An endocrine disruptor is 
defined as “an exogenous substance or mixture that alters the function(s) of the 
endocrine system and consequently causes adverse health effects in an intact 
organism, or its progeny, or (sub)populations” (80, 81). 
 
Figure 10. The structures of BPA and estradiol have some structural similarities, thus BPA 
has the ability to bind to estrogen receptors. 
 
Due to its structural analogy to estradiol (two phenol functional groups and two 
benzene rings) (Figure 10), BPA can bind to estrogen receptors (ERα and ERβ) and 
act as a weak estrogen as well as an antiestrogen, blocking the estrogenic response 
(78, 79) (Figure 11). Further, BPA has been shown to bind to thyroid receptors and 
might interfere with thyroid function (82). BPA can also interact with the immune 






Figure 11. Mechanism through which endocrine disruptors can influence the endocrine 
system after being absorbed by the body. Figure modified from (84). 
  
Concern has been raised about the potential human health risk of low-level exposure 
to BPA. It has been reported that the biological effects of BPA show a nonmonotonic 
dose-response curve, a pattern that is characterized by intense reactivity at low levels 
and no or less response at high levels (83, 85).  
The results of numerous in vitro and animal studies have demonstrated an association 
between low-dose exposure to BPA and a variety of negative outcomes (86, 87). In 
fact, some studies show effects from doses that are comparable to calculated human 
exposures (i.e. doses <10 microgram per kilogram bodyweight (µg/kg bw) per day) 
(86-88). In several epidemiological studies, BPA levels in human populations have 
been linked to reproductive abnormalities, adverse developmental effects, metabolic 
disease, and breast cancer among other health conditions (89-91). The mechanisms of 






Assessment of low-dose effects from BPA has been disputed (92), and represents a 
challenge for the traditional regulatory health risk assessment (93, 94). To assess the 
risk of serious negative effects to human health, it is important to consider the 
concentration of unconjugated BPA in the circulation.  
The current opinion of risk assessment agencies, such as the European Food Safety 
Authority (EFSA), is that negative health effects from BPA exposure cannot be 
excluded (95). In 2015 the EFSA reduced the recommended Tolerable Daily Intake 
of BPA from 50 to 4 µg/kg bw per day (95). However, there is still some debate 
regarding this estimated safe level of BPA exposure. Although unconjugated BPA 
has been detected in blood in several studies (94), other authors have claimed that the 
observed unconjugated BPA concentration resulted from contamination of the 
samples during storage or sample preparation (67, 96). Nevertheless, in 2017, based 
on the scientific evidence of probable serious effects to human health, the Member 
State Committee of the European Chemical Agency (ECHA) decided to label BPA as 
a substance of very high concern (80). Currently, since November 2018, a working 
group from the EFSA is re-evaluating the potential hazards of BPA in food based on 
studies and data published after 2012. The updated assessment is expected to be 
completed in 2020 (97).  
Human intake of BPA has generally been estimated in two different ways (56). In the 
biomonitoring approach, concentrations of total BPA (unconjugated + conjugated) 
measured directly in human tissues (e.g. urine, blood) are used to estimate (back 
calculate) the total exposure from all possible sources. Studies using this approach 
have estimated exposures in a range from 0.02 to 0.03 µg/kg bw per day among 
adults in the United States and Japan (98-100), to 0.04 µg/kg bw per day among 20–
29-year-old students in Germany (101), and to 0.07 µg/kg bw per day among 6–8-
year-old girls in the United States (102). In the aggregating approach (forward 




through different exposure pathways. This method requires sources of exposure to be 
identified and measured. Using this method, the estimated exposure ranges from 0.04 
to 0.06 µg/kg bw per day (103) to 1.4 µg/kg bw per day for adults consuming canned 
food (high exposure group) (104). Calculations based on biomonitoring are preferred 
for estimating total intake because all sources of exposure are accounted for. 
However, estimates based on sources of exposure are useful for calculating the 
relative contributions of various exposure pathways to total intake. 
Biomonitoring data show that human exposure to BPA is widespread, and more than 
90% of the populations in the United States and Canada have measurable BPA 
concentrations in their urine (98, 105). Of particular concern has been exposure 
during vulnerable periods of life, such as during fetal and early postnatal 
development (106-108) because fetuses and neonates might have reduced capability 
to metabolize and excrete BPA from the body compared with older individuals (109). 
Moreover, studies have reported that BPA might cross the placental barrier (110, 
111). Thus, exposure to BPA during pregnancy might pose a potential risk to the 
vulnerable fetus, and there is a need to identify sources of BPA and their relative 
contributions to the total exposure.   
The recommendation in the National Clinical Guideline for dental restorative 
treatment, published by the Norwegian Directorate for Health and Social Affairs in 
2003, was to avoid placement of dental fillings during pregnancy (112). According to 
the Directorate, this recommendation is based on the precautionary principle, and 




The Norwegian Mother and Child Cohort Study is an ongoing prospective 
population-based cohort study conducted by the Norwegian Institute of Public Health 
(NIPH) (113, 114). From 1999 to the end of 2008, pregnant women in Norway were 
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invited to MoBa through a postal invitation in connection with their first routine 
ultrasound examination. Approximately 41% of pregnant women attended the study, 
and the cohort currently comprises more than 108,000 pregnancies, 114,000 children, 
95,000 mothers and 75,000 fathers (113). Approximately 16,400 women participate 
with more than one pregnancy.  
The main aim of MoBa is to find causes of serious diseases, with a focus on the 
interplay between early exposures and genetic factors. The NIPH intends to follow 
the families for years to come and to create a Norwegian research database of high 
quality. 
MoBa is mainly based upon self-reporting through questionnaires. Written informed 
consent was obtained from each participant upon recruitment. During pregnancy, the 
mother provided answers to three questionnaires that focused on different exposures 
as well as health-related history, whereas the father responded to one questionnaire 
on medication, health, and occupational exposure. Additional questionnaires on the 
development of the child, the health of the mother and the child and lifestyle 
exposures are sent out at regular intervals (Figure 12). Apart from this, blood and 
urine samples were collected from both parents during pregnancy and from the 
mother and child after birth. All biological samples are stored in a biobank. At the 
age of 6–7 years, children participating in MoBa were asked to supply one or more 
primary teeth (115). Additional data and biological materials have also been collected 
in numerous sub-studies. Moreover, MoBa is linked to several national health 
registries such as the Medical Birth Registry of Norway (MBRN) (116), the National 
Patient Registry, the Norwegian Prescription Database, and the Cancer Registry 






The overall aim of this thesis was to gain knowledge about the exposure to BPA from 
dental polymer-based restorations in humans and to investigate whether placement of 
polymer-based dental fillings during pregnancy is associated with increased risk for 
adverse birth outcomes. 
 
The specific aims were: 
 
 To quantify salivary concentrations of BPA and to assess if presence of dental 
polymer-based filling materials is associated with increased BPA levels in saliva 
(Paper I).  
 
 To quantify BPA concentrations in saliva and urine before and after treatment 
with dental polymer-based restorative materials to assess if placement of these 
materials is associated with increased BPA levels in saliva and urine (Paper II). 
 
 To investigate whether the placement of polymer-based dental fillings during 
pregnancy is associated with adverse birth outcomes including stillbirth, preterm 





The material and methods used in the included studies are described in the respective 
papers. Here follows a brief summary.  
 
 
Individuals between 20 and 35 years of age were recruited to the study from three 
public dental clinics during their routine dental check-ups. Patients fulfilling the study 
inclusion criteria were included from January 2013 to March 2014. Twenty 
individuals who had six or more tooth surfaces previously filled with dental polymer-
based materials were enrolled in the composite group. The fillings had to be 1 week 
or older. Twenty patients without dental polymer-based materials were included in 
the comparison group. Subjects with chronic disease and/or current medications were 
not included. Exclusion criteria were smoking, use of snuff, drug abuse, use of dental 
splints, dental prostheses, and previous or current orthodontic treatment. In addition, 
dental students and dental health workers were not included. All participants provided 
written informed consent. 
Clinical examination 
Before clinical examination of each participant, intraoral radiographs taken during the 
routine check-up were reviewed in order to detect and verify existing fillings. The 
total number of teeth, pre-filled surfaces, and, if available, type of restorative 
materials used, and time of last filling placed were recorded during a detailed dental 
examination. Each filling surface was assigned a score from 1 to 3 depending on the 
extent of the surface area, yielding the variable “filling points” (117). Small filling 
surfaces were designated the lowest score of 1. The score of 2 was typically given to 
surfaces of intermediate size (e.g. approximal or occlusal surfaces of premolars). 
Restorations in molars extending over the total occlusal fissure system or over the 




Collection and analysis of saliva samples 
All participants were instructed to refrain from eating, drinking, brushing their teeth, 
using lipstick, etc., for at least 2 hours before sampling. On the day of sampling, the 
participants were asked (see Appendix I) about exposures that potentially could 
contribute to salivary BPA concentration. Potential variables were dichotomized into 
groups: Intake of breakfast before sampling (yes/no), intake of canned food in the last 
week (yes/no), job that involved handling of receipts (yes/no), and use of chewing 
gum daily (yes/no).  
Saliva was collected at the dental clinic while the participant was seated in a dental 
chair (Figure 13). The individuals were encouraged to make active cheek and tongue 
movements for one minute, and the accumulated saliva was collected in a 
polypropylene tube until 5 ml were sampled. The sampling time was recorded. Each 
sample, marked with an ID code and date, was immediately placed in a refrigerator 
(4°C) and then stored at −80°C until they were sent for analysis. The saliva 
specimens were analyzed at the Laboratory of the Division of Occupational and 
Environmental Medicine at Lund University, Sweden, using liquid chromatography-
triple quadrupole mass spectrometry (LC/MS/MS; QTRAP 5500; AB Sciex, Foster 
City, CA, USA). The laboratory is a European reference laboratory for BPA in urine 
(http://www.eu-bm.info/democophes) and a reference laboratory for BPA in urine in 
the Erlangen round robin inter-laboratory control program. For determination of total 
BPA in saliva, aliquots were digested with glucuronidase and an isotopically labeled 
internal standard for BPA (D16-BPA) was added. Proteins were precipitated using 
acetonitrile. Unconjugated BPA was determined without the use of glucuronidase. 
The difference between total and unconjugated BPA represented the concentration of 
conjugated BPA. The limit of detection (LOD) was determined to be 0.1 ng/ml. For a 








Figure 13. Collection of saliva using a polypropylene tube. Photos: TLL Berge 
 
 
Twenty healthy patients 16–40 years of age who were provided a treatment plan for 
at least one dental restoration (two or more surfaces) with polymer-based filling 
material were recruited to the study from two public dental clinics during their 
routine dental check-ups. Smokers, snuff users, drug abusers, dental students, dental 
health workers, subjects with removable dentures or dental splints, who were 
undergoing orthodontic treatment, or who had polymer-based fillings placed during 
the previous 3 months were not included. Individuals fulfilling the selection criteria 
were consecutively included from January 2016 to November 2017. All participants 
provided written informed consent. 
Clinical examination and dental treatment 
Each participant underwent a detailed dental examination where the number of 
previously filled tooth surfaces and, if available, the type of preexisting restorative 
materials was recorded by one dentist. The same dentist performed the dental 
treatment at one public dental clinic. Tooth preparation, restoration, and polishing 
were performed in an ordinary clinical setting and according to standardized 
procedures and materials used at the clinic. High-volume evacuator equipment was 




dam isolation was not used. A three-step etch-and-rinse procedure (ANA Etching Gel 
37%, Directa, Upplands Väsby, Sweden, and OptiBond FL, Kerr, USA) was 
performed. The same batch of a widely used bis-GMA-based material (Tetric 
EvoCeram, 0.2 g compules, Color A2, LOT 014504, Ivoclar Vivadent AG, 
Liechtenstein) was used throughout the study. Material compositions based on the 
manufacturer’s user manual and safety data sheet are provided in Table 3. For each 
patient, filling material from a discrete compule was inserted in incremental layers. 
Each layer was cured with the light intensity and exposure time recommended by the 
manufacturer. Care was taken to reduce excess material, and any surplus was 
removed from the filling surface and put back into the compule. The need for 
adjustment of the fillings was marginal. The amount (weight in grams) of material 
used in each participant was estimated by weighing each compule before and after 
treatment. The dental curing lamp was controlled for acceptable light intensity prior 
to each treatment session using a single dental radiometer. The extent of each filling 
surface was estimated by giving the area scores from 1 to 3 (“filling points”) as 
described for Paper I (117).  
 
Table 3. Composition of Tetric EvoCeram based on the manufacturer’s “Instructions for 
Use” and the safety data sheet. 
Composition Ingredients Content, weight (%) 
Polymer matrix Bis-GMA 3–<10 
Bis-EMA 3–<10 
UDMA 3–<10 
Additives, initiators, stabilizers, pigments <1 
Inorganic fillers 
(particle size range between 
40 nm and 3 µm) 
Barium glass 
82–83 Ytterbium trifluoride  








Collection and analysis of saliva and urine samples 
The participants were instructed to refrain from eating, drinking, brushing their teeth, 
using lipstick, etc., for 10 hours prior to sampling. All treatment and sampling 
sessions were scheduled for the morning. 
Information about the participants’ dental hygiene habits and if they handled receipts 
at work was obtained. In addition, on each day of sampling the individual’s 
consumption of canned and microwaved food during the previous 24 hours and 
previous week was recorded (see Appendix III). The participants were instructed to 
empty their bladder during the early morning at home. Each participant provided a 
total of five saliva samples and four urine samples. The first saliva and urine samples 
were collected immediately before treatment. Sampling of a second saliva sample 
was started 10 minutes after placement of the polymer‐based fillings, and subsequent 
saliva and urine samples were collected 1 hour, 24 hours, and 1 week after placement 
of the fillings (Figure 14). Field blanks, samples from the cooling water, and water 
from the dental unit were also collected, treated, stored, and analyzed in the same 
manner as the biological samples. 
 
 




Saliva specimens (2 ml) were collected using the same procedures and instructions as 
described in Paper I. No gargling was allowed in the time period between placement 
of the fillings and the saliva sampling 10 minutes after treatment. Urine specimens 
were collected in 100 ml polypropylene cups. Immediately after collection, the 
samples were refrigerated at 4°C and within the same day transferred into 15 ml 
polypropylene tubes and stored at −80°C until they were sent to the laboratory for 
analysis.  
Determination of BPA in saliva and urine  
Urine and saliva samples were analyzed at the reference laboratory in Lund, Sweden, 
using LC/MS/MS as described in Paper II and Appendix IV. The LOD was 
determined to be 0.1 ng/ml. Field blanks, laboratory blanks, and two different in-
house-prepared quality control samples were analyzed in the analytical batches. The 
within-run and between-day precision was acceptable. The concentration of BPA in 
urine was adjusted for urinary density (118).  
For quality control, some of the saliva samples, representing the full range of salivary 
BPA concentrations detected in Lund, were analyzed at an independent laboratory 
(Nordic Institute of Dental Materials, Oslo, Norway) using LC/MS/MS. 
 
 
Study III was based on data from MoBa (version 8 of the quality-assured MoBa data 
files) (113, 114) and from the Medical Birth Registry of Norway (MBRN) (116). 
Self-reported information from the participating women was obtained from two of the 
questionnaires (Q1 and Q3) responded to during pregnancy week 17 and 30, 
respectively (Figure 12 and Appendix V). Only singleton births were included in the 






Figure 15. Flowchart showing the number of participants included in Study III and the 
groups available for analyses. 
 
Exposure variable 
White fillings placed during pregnancy was the exposure variable, and data on dental 
treatment during pregnancy were obtained from Q3. The women reported if they had 
consulted a dentist during pregnancy (Q3c, in the English version, Question 34: 
“Have you been to the dentist during this pregnancy? Yes/No”) and if so, whether 
they had received white dental fillings (Question 35c: “If, yes, did the dentist perform 
any of the following treatment? New white fillings placed? (Yes/No”) (See Appendix 




consult a dentist during pregnancy (reference category), participants who consulted a 
dentist but had no white fillings placed, and participants who consulted a dentist and 
had white fillings placed (Figure 15). Participants with missing data on birth 
outcomes or with unacceptable information about dental treatment during pregnancy 
were excluded, leaving a study population that included 90,886 pregnancies (Figure 
15). 
Outcome variables 
Information about pregnancy outcomes (stillbirth, preterm delivery, malformations, 
birth weight) was gathered from the MBRN (116). Stillbirth was defined as the death 
of a fetus with a gestational age of 22 weeks or more or with a birth weight of 425 g 
or more. Gestational age was estimated from the ultrasound examination in the 17th 
week of pregnancy. Information on last menstrual period was used if an ultrasound 
investigation had not been performed. Infants born prior to or during gestational week 
32 were classified as very preterm, and if they were born between gestational week 
33 and 37 they were classified as late preterm (119, 120). All diagnoses from the 
MBRN records are based on the International Statistical Classification of Diseases, 
10th Revision (ICD-10) (121). Malformations were defined as any birth defects 
registered in the MBRN. Infants were classified as low- and high-birth weight infants 
according to the World Health Organization’s (WHO’s) recommended definitions 
(122). They were defined as small for gestational age if they were less than the 10th 
percentile and large for gestational age if they were larger than the 90th percentile 
(119, 120). Newborns with weight below the 2.5th percentile were defined as very 
small for gestational age (122). 
Potential confounding variables 
The following potential confounders were included in the analyses: parity, mother’s 
age at delivery, maternal body mass index (BMI; kg/m2), education, smoking habits, 
and alcohol consumption during pregnancy. Information about parity was based on 




number of former births (with a gestational age of 12 weeks or more) and divided 
into two categories (none and one or more). Information about the mother’s age at 
delivery was gathered from the MBRN and divided into six categories (≤19, 20–24, 
25–29, 30–34, 35–39 and 40+ years). Data on maternal height, pre-pregnancy weight, 
education years, smoking habits, and alcohol consumption during pregnancy were 
obtained from Q1. Maternal BMI was calculated and categorized according to the 
WHO classification (123). Maternal education and maternal smoking were divided 
into three categories (≤12, 13–16, and ≥17 years) and (never, occasionally, and daily), 
respectively. Maternal alcohol consumption was divided into four categories (never, 
less than once a week, once a week, and more than once a week). 
  
 
Analyses were performed using the statistical software program SPSS (IBM SPSS, 
New York, USA) version 21 in Paper I, version 25 in Paper II, and version 24 in 
Paper III. For the power calculation, IBM-SPSS Sample Power (release 3.0.1) was 
used. For the mixed effect analyses in Paper II Stata (Stata corp., Texas, USA) 
version 15 was used. P-values less than 0.05 were considered statistically significant.  
Power and sample size considerations 
At the time Study I and Study II were planned, we found no published data that could 
be used for power calculations. Thus, the following assumptions were made.  
For Study I, it was assumed that 75% of the individuals in the group with polymer-
based dental fillings had detectable concentrations in saliva and that 25% of the 
individuals in the group without such restorations had detectable concentrations. If 
such were the case, a study with 20 individuals in each group would have 96% power 





For Study II, it was assumed that 70% of the individuals had values below the LOD 
in saliva prior to the treatment and above the LOD after the treatment and that 10% of 
the individuals had values similar to or above the LOD prior to the treatment and 
values below the LOD after the treatment. It was also assumed that 20% of the 
individuals showed no changes and thus either had values below the LOD prior to 
and after the treatment or they had values above the LOD prior to and after the 
treatment. Using these assumptions, a study including 20 individuals would have 
97% power to detect a significant result (with alpha set to 0.05 and using a one-sided 
McNemar test). 
Numerical variables were presented as means, minimum and maximum values, and 
standard deviations (SDs). Categorical variables were presented (summarized) as 
numbers and percentages.  
In Study I and II, values below the LOD were set to one half of the LOD in the 
statistical analysis (124). 
 
 
The main hypotheses to test were H0: There is no difference in BPA concentration in 
saliva between the composite group and the comparison group, and H1: The BPA 
concentration in saliva is higher in the composite group compared to the comparison 
group.  
Differences in salivary BPA concentrations (the dependent variable) between 
exposure groups (composite group vs. comparison group) and other groups based on 
background characteristics that potentially could contribute to salivary BPA 
concentration (see Table 2 in Paper I) were assessed using the Mann–Whitney U-test 
(125). Spearman rank correlation was used to test the correlation between salivary 




polymer-based filled surfaces, number of polymer-based points, time since last filling 
placed, time of day of saliva sampling, saliva collection duration, and saliva secretion 
rate. The chi-square test was used to assess differences in proportions of detectable 
concentrations between groups, and logistic regression analysis was performed to 
calculate odds ratios (ORs) for having detectable concentrations of BPA in saliva. 
 
 
The primary hypotheses to test were: H0: There is no difference in BPA concentration 
in saliva before and after treatment with dental polymer-based restorative material 
and H1: The BPA concentration in saliva increases after treatment with dental 
polymer-based restorative material. In addition, changes in BPA concentrations in 
urine before and after treatment with dental polymer-based restorative material were 
analyzed. 
Linear mixed effects regression models were applied for the analyses of repeated 
measures of the BPA concentration in saliva and urine. In the models, the repeated 
nature of the measurements of the data were accounted for using the participant’s ID, 
entered as a random factor, with an additional factor for time to account for the 
difference in variation over time.  
The time point for the measurements was considered a categorical variable 
comparing the succeeding measurements with the pretreatment value. All available 
data, including data for participants with missing observations at some time points, 
were used in the model. Furthermore, the analyses were extended to explore whether 
other variables were significant in addition to time point (see Table 1-3 in Paper II).  
 
Logistic regression analyses were performed to evaluate whether dental treatment 
with polymer-based material (white fillings) during pregnancy was associated with 
risk for adverse birth outcomes (stillbirth, preterm birth, malformation, and low or 
high birth weight). The outcomes (dependent variables) were dichotomized as present 
(1) or absent (0).
Odds ratios with 95% confidence intervals (CIs) were calculated. The OR was 
adjusted for maternal age, education, pre-pregnancy BMI, parity, smoking during 
pregnancy, and alcohol consumption during pregnancy. The OR expresses 
differences in the risk of presenting with the outcomes between categories of the 
independent variables (Did not consult a dentist during pregnancy; Consulted a 
dentist, no white fillings placed; Consulted a dentist, white fillings placed). An OR >1 
indicated an increased risk, whereas OR <1 indicated a decreased risk. A non-
significant outcome was understood if 1 was included in the 95% CI.  
The ethical considerations were in accordance with the Declaration of Helsinki. 
Participation was voluntary and based on written informed consent, and all 
participants were allowed to withdraw from the studies without giving any reason and 
without any negative impact for the individual. Study protocols were reviewed and 
approved by The Regional Committees for Medical Research Ethics (REK), Norway 
(Approval numbers for Study I: REC South-East B, 2012/602; for Study II: REC 
South-East B, 2014/1529; for Study III: REC South-East D, 2011/727). 
Study II was registered at ClinicalTrials.gov, number NCT02575118. 
Search for literature ended 19th June 2019 
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This section gives a brief summary of the results presented in the three papers that 
constitute this thesis. 
The participants had a mean age of 24.2 years ranging from 20 to 34 years in the 
composite group and from 20 to 35 years in the comparison group. Women 
predominated in both groups. The participants in the composite group had a mean of 
12.3 (SD = 4.7) surfaces previously filled with dental polymer-based material, which 
corresponded to a mean sum-score of 32.2 (SD = 15.2) filling points. The fillings had 
been placed from 1 week to several years before inclusion in the study. The mean 
salivary flow rate was similar in the two groups. The salivary BPA concentration was 
very low in both groups, and most values were below the LOD of 0.1 ng/ml. In the 
composite group, 8 of 20 (40%) had detectable concentrations of BPA in their saliva 
compared to 3 of 20 (15%) in the comparison group.  
The composite group had a marginally higher concentration of BPA in their saliva 
(0.12 ng/ml) compared with the comparison group (below the LOD) (p = 0.044, 
Mann–Whitney U-test; one-sided exact test). Practically all BPA in the saliva 
samples was unconjugated, and conjugated BPA was generally not detected. When 
examining other potential variables that might contribute to the variation of 
unconjugated BPA in saliva, only intake of breakfast showed a statistically significant 
effect (p = 0.003, Mann–Whitney U-test). The correlation between BPA level in 
saliva and the number of surfaces filled with polymer-based material was not 
statistically significant (Spearman correlation coefficient 0.209; p = 0.195). Neither 
was the correlation with the surface area of the polymer-based fillings (as measured 
by the number of filling points) (Spearman correlation coefficient 0.245; p = 0.299). 
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The majority of the participants were women and the mean age was 23.4 years with a 
range of 17 to 36 years. The participants had a mean of 11.8 (SD = 9.6) pre-existing 
tooth-colored filling surfaces, corresponding to 25.7 (SD = 21.7) pre-existing filling 
points. In the present study, the mean number of tooth-surfaces restored with 
polymer-based filling material was 2.7 (SD = 1.9), corresponding to 7.7 (SD = 0.7) 
filling points. The mean weight of polymer-based material placed in each participant 
was 0.158 g (SD = 0.067).  
One saliva sample collected before treatment was excluded from the statistical 
analysis due to probable contamination. In addition, one saliva sample and one urine 
sample, collected from one participant at 1 week after treatment, were excluded 
because the participant had eaten breakfast before sampling.  
Concentration of BPA in saliva 
The pretreatment (baseline) levels of salivary BPA were very low, and 11 of 20 
participants had values below the LOD. The estimated mean value was 0.11 ng/ml. 
Compared to the pretreatment levels, the salivary BPA concentration in the samples 
collected 10 minutes after treatment increased significantly (the mean concentration 
was 385 ng/ml; p < 0.001). Following the immediate posttreatment increase, the BPA 
concentrations in saliva decreased exponentially with time. However, compared to 
pretreatment levels, the concentration remained significantly elevated at 1 hour, 24 





Figure 16. Salivary concentrations (ng/ml) of free (unconjugated) BPA among participants 
in Study II (individual patterns) before (baseline) and at 10 minutes, 1 hour, 24 hours, and 1 
week after treatment with polymer-based filling material (n = 20).  
 
The secondary explorative analyses indicated that the surface area of the new fillings 
(as expressed by the number of filling points) was associated with the salivary BPA 
concentrations measured at 24 hours and 1 week after treatment. There were no 
statistically significant associations between the other variables tested and the BPA 
levels in saliva at the different time points.  
Concentration of BPA in urine 
The vast majority of participants (19 of 20; 95%) had detectable BPA concentrations 
in their urine prior to the placement of polymer-based dental material. The calculated 
mean concentration was 1.41 ng/ml. There were no statistically significant 




(Figure 17). The BPA levels in urine samples collected 1 hour after treatment did not 
show an association with the BPA levels in the saliva samples collected at 10 minutes 




Figure 17. Urine concentrations (ng/ml) of total BPA among participants in Study II 
(individual patterns) before (baseline) and at 1 hour, 24 hours, and 1 week after treatment 
with polymer-based filling material (n = 20). 
 
As illustrated in Figure 17, showing BPA concentrations in urine over time, two of 
the participants had remarkably higher BPA levels compared to the other participants. 
Both of these were among five participants who reported handling cash register 
receipts at work. The participant with the highest BPA concentration in urine was 
also the one with the highest levels of BPA in saliva at all time points. Using 
handling of receipts as a categorical variable, an overall elevated average level of 
urinary BPA was found for the group handling receipts (p = 0.031, mean difference 




Among the 90,886 included women, a dentist consultation during pregnancy was 
reported by 33,727 women. Of these, 10,972 reported having white fillings placed 
(Figure 14). Of the included pregnancies, 29,387 (51.4%) resulted in the birth of a 
boy. The proportion of stillbirths, very preterm births, and late preterm births was 
0.2%, 0.6%, and 3.8%, respectively. Malformation was registered in 4.8% of the 
infants. 
No associations between the placement of dental polymer-based fillings (white 
fillings) during pregnancy and adverse birth outcomes were observed.  
Gender-specific analysis showed that girls born to mothers who received white 
fillings during pregnancy had an increased risk of being small for gestational age 
(below the 10th percentile) compared to the reference group (mothers who did not 
consult a dentist during pregnancy). The unadjusted OR was 1.14 (95% CI 1.01–1.28; 
p = 0.029). After adjustment for potential confounders, the OR was reduced and not 
statistically significant (OR = 1.10, 95% CI 0.97–1.24). Boys born to mothers who 
had white fillings placed during pregnancy had a marginally increased risk of being 
born late preterm compared to the boys born in the reference group. The unadjusted 
OR was 1.16 (95% CI 1.01–1.34; p = 0.041), and the adjusted OR was 1.13 (95% CI 





This thesis is based on three papers. Paper I and Paper II describe two separate 
clinical studies focusing on BPA exposure from dental polymer-based filling 
materials in humans. Paper III presents a study investigating whether placement of 






The study presented in Paper I was designed as a cross-sectional study with one 
exposed group (composite group) and one unexposed group (comparison group). The 
aim was to evaluate if the presence of dental polymer-based fillings aged 1 week or 
older was associated with increased BPA levels in saliva. Patients who were 
scheduled for a routine dental check-up and who met the inclusion criteria were 
consecutively invited to the study. Hence, the study participants were recruited using 
convenience sampling. Because there was no follow up, fewer resources were 
required to run the study. Thus, the cross-sectional design made the study relatively 
fast and inexpensive to perform. The inclusion of an unexposed comparison group 
was advantageous for determining the effect of other potential variables that might 
contribute to the salivary BPA concentration. However, because the relationship 
between the presence of dental polymer-based fillings (exposure/dependent variable) 
and salivary BPA concentration (outcome/independent variable) was measured at a 
single point in time, only an association and no causation could be inferred from the 
study. On the other hand, results from this cross-sectional study might be useful to 






The study presented in Paper II could be described as a prospective descriptive 
observational cohort study and was designed to evaluate whether placement of dental 
polymer-based fillings was associated with increased BPA levels in saliva and urine. 
The prospective design, observing BPA concentrations at multiple time points, 
allowed trends in the concentrations over time to be monitored.  
The participants were recruited consecutively after routine dental check ups by their 
own dentist if they were provided a treatment plan for at least one dental restoration 
(two or more surfaces) of polymer-based filling material and otherwise fulfilled the 
selection criteria. The dental treatment procedures and the dental filling material used 
were in line with current clinical practice. Thus, the therapeutic intervention, i.e. 
placement of polymer-based restorations, was not assigned by the researcher and the 
study could thus be considered an observational study. The use of only two dental 
clinics for recruitment of participants and one single operator made it easy to 
stadardize the assessments and procedures in the study. 
In this study, the individuals served as their own controls (i.e., measures before 
versus after treatment). Thus, the background variation in an unexposed comparison 
group did not have to be considered. However, including an unexposed comparison 
group would have strengthened the study design and made it easier to interpret the 
contribution of BPA from the dental polymer-based material to urinary BPA levels. 
 
 
In Paper III, the results from an observational cohort study evaluating associations 
between placement of polymer-based fillings during pregnancy and adverse birth 
outcomes are presented and discussed. In this study, data from MoBa (113, 114) were 
used. The main strengths of the study were the large sample size, the large number of 




MBRN (116). This made it possible to observe rare birth outcomes and to control for 
potential confounding variables. Moreover, the prospective design of the study 
reduced the risk of possible recall bias. A limitation of MoBa is the low response rate 
(41%), which might give rise to selection bias. Potential self-selection of the 
healthiest women has been discussed previously (126). MoBa participants are older 
and better educated and comprise a higher percentage of non-smokers compared to 
non-participants. However, self-selection is not considered to be a validity problem in 
studies of associations between exposure and outcomes in MoBa (126). Another 
limitation of the present study is that MoBa is based upon self-reporting. This is 




Currently there is a wide range of dental polymer-based restorative materials 
available. Most of them are bis-GMA-based and thus have the potential to release 
small amounts of BPA (14, 45). Study II was designed to reflect an ordinary clinical 
situation using a representative bis-GMA-based restorative filling material. The aim 
of the study was not to compare the release of BPA from different dental polymer-
based materials. The material was selected based on the indications specified by the 
manufacturer, as well as which restorative polymer-based material was reported to be 
the most commonly sold in Norway during 2013 (Communication by e-mail to LIC 
Scadenta and Plandent, the two largest dental suppliers in Norway, 08 May 2014). 
The same batch of a bis-GMA-based material (Tetric EvoCeram, Color A2, LOT 
014504, Ivoclar Vivadent AG, Liechtenstein) was used for all participants throughout 
the study. Using one batch of one dental polymer-based material strengthened the 
internal validity of the study. However, the external validity of the study is limited. 
The potential to release BPA might vary between dental polymer-based materials due 








To reduce BPA exposure from other sources, the participants in Study I and II were 
instructed to avoid food and drink intake prior to sampling. For Study I, it was 
expected that a 2-hour clearance should be sufficient to avoid influence from the 
dietary intake. However, the results from Study I suggested that intake of breakfast 
had a statistically significant effect on the BPA concentrations in saliva and thus 
indicated that 2 hours of food restriction might not be sufficient. Hence, in Study II 
the participants were instructed to refrain from food and drink intake 10 hours 
(overnight) before the scheduled sampling. Furthermore, it cannot be excluded that 
the time of day of saliva sampling might influence the salivary BPA concentration 
(Paper I, Table 3, rs = 0.275, p = 0.086). The indoor air might be a source of BPA 
exposure (127, 128), and thus it could be speculated that the concentration of BPA is 
likely to become higher throughout the day in dental clinics. For this reason, all 
participants in Study II were scheduled in the morning before 9 a.m. In addition, they 
were instructed to put the cap back on the tube between each spitting during the 
saliva sampling. 
The participants in Study I and II were asked to provide 5 ml and 2 ml saliva samples, 
respectively. The duration of the sampling varied between and within participants and 
could potentially affect the BPA concentration. However, no statistically significant 
correlation between salivary BPA concentration and sampling time was found. 
 
The overall aim of Study I and II was to assess if dental polymer-based fillings have 
the potential to contribute to human BPA exposure. To evaluate potential exposure, 
saliva and urine were collected.   
Saliva embraces the teeth and is in direct contact with the dental fillings. Therefore, 
salivary BPA concentrations should be a good indicator of BPA exposure from dental 
polymer-based restorations and might reflect the highest measurable level of the 
biologically active form of BPA (unconjugated BPA) released into the oral cavity. 
Moreover, saliva provides non-invasive, rapid, economical, and easy sampling (129). 
Although saliva is considered a useful matrix, high inter- and intra-individual 
variability have been reported in different clinical studies examining saliva 
concentrations of leachable chemicals from dental polymer-based materials (29, 44, 
130) and might pose a challenge. Even though the sampling procedure was 
standardized, considerable variation between individuals was observed (Figure 16). 
Blood and urine have generally been the matrices used to monitor levels of most toxic 
compounds (131). Urine, like saliva, provides non-invasive, quick, economical, and 
easy sampling. Ingested BPA is considered to be rapidly absorbed, conjugated, and 
excreted in the urine within 24 hours after exposure (64, 73, 77), but the validity of 
studies examining BPA levels in human blood after oral administration has been 
disputed (52, 132). The controversies have mainly been related to the analytical 
methods used as well as to concerns regarding possible BPA contamination from the 
materials/equipment used for the sampling and processing procedures (52, 67, 133-
136). Moreover, blood sampling is time-consuming, invasive, and might be 
associated with anxiety for some individuals.   
BPA is mainly present as the conjugated form in human urine. Thus, the potential 
external contamination (unconjugated form) as suggested regarding blood samples is 





Furthermore, two previous clinical studies assessing BPA exposure after dental 
treatment with polymer-based materials were not able to detect any BPA in blood 
(137, 138). The authors speculated that the lack of detectable values of unconjugated 
BPA in blood was probably due to relatively low exposure doses or rapid metabolism 
of BPA.  
Because excretion of BPA in the urine is almost complete within 24 hours and 
because urine offers several advantages compared to blood, urine was the matrix of 
choice for assessing potential systemic exposure to BPA in Study II. 
 
 
A European reference laboratory for BPA in urine performed the analysis of the 
biological samples in Study I and II. To achieve high sensitivity and high specificity, 
LC/MS/MS with an isotopically labeled internal standard (D16-BPA) was used. The 
LC/MS/MS is the method of choice for the determination of BPA in biological 
samples (139). BPA is a widespread chemical, and it might be found ubiquitously. To 
confirm the validity of the analysis and to identify potential contaminants, quality 
control samples and field blanks were analyzed together with the samples of saliva 
and urine. The LOD of the method was low and the analysis had high precision and 
low variability. In addition, the levels of salivary BPA concentrations in Study II 
were confirmed by an independent laboratory (Nordic Institute of Dental Materials). 







MoBa is based on self-administered questionnaires designed to be completed by the 
respondent without the intervention of the researchers collecting the data (114). To 
obtain reliable answers from the participants, efforts were made to formulate the 
questions to be as comprehensible as possible. In Norway, the term “white fillings” is 
practically synonymous with dental polymer-based restoratives or so-called dental 
composites. Thus, to gain knowledge about treatment with dental polymer-based 
material during pregnancy, the women were asked if they had received white dental 
fillings while pregnant (see Appendix V). The use of “white fillings” as an exposure 
indicator was discussed and elaborated in Paper III. The term may include other 
tooth-colored dental materials such as resin-modified cements, compomers, and 
conventional glass-ionomer cements and could potentially give rise to 
misclassification. However, studies investigating treatment concepts for dental caries 
in Norway during the MoBa enrolment period showed that the vast majority of 
responding dentists preferred polymer-based material when restoring permanent teeth 
(140-142). Although access to dental records with detailed information about dental 
restorative treatment (e.g. which polymer-based materials were used and number and 
extension of restorations) would have been preferable, this would be unachievable in 
such a large epidemiological study as MoBa. Hence, information about possible 
previous dental restorative treatment, the exact number and extension of the fillings 
as well as the types and brands of materials placed during pregnancy, is lacking.  
 
 
The participants were asked to report dental treatment during the first 30 weeks of 
pregnancy. However, they were not asked to specify the exact day or week of 




placement of dental polymer-based materials plays important roles at specific time 
windows over the course of pregnancy. The effects of prenatal exposure to toxic 
agents might be considerably influenced by the degree and timing of exposure during 
gestation (143). Some teratogen agents cause adverse effects only during a “critical 
window” which may be certain days of early development of the fetus when a 
particular part of the fetus’ is developed (143). The Thalidomide tragedy in the late 
1950s and the early 1960s is a well known example. Maternal intake of the 
medication between day 20 and day 36 after fertilization resulted in serious 




In Study I, the data set was relatively small, and the groups were considered 
independent. Most of the values were below the LOD and the data were accordingly 
skewed. Thus, the non-parametric Mann–Whitney U-test, which does not assume a 
normal distribution, was used to compare the groups (125). Non-parametric tests are 
generally less powerful than parametric tests with regard to the detection of existing 
differences. On the other hand, they are less affected by extreme observations. Taking 
into account that the conditions for using a parametric test were not met and that the 
data set was small, Spearman rank correlation was the natural choice to test 
correlations between variables. 
There was no reason to believe that the composite group, exposed to dental fillings 
known to contain impurities of BPA would have lower salivary BPA concentration 
compared to the comparison group without such fillings. Thus, formulation of a one-




excluded the possibility to study if the comparison group would have higher 
concentration of BPA in saliva compared to the composite group. 
 
 
In Study II, multiple values from each individual measured at specific time points 
were analyzed. Some of the measurements were excluded due to non-compliance and 
suspicion of contamination. Thus, of the 20 individuals, only 18 of them had 
complete data. Use of analysis of variance for repeated measures would thus be based 
only on the 18 individuals. In an effort to keep as much data as possible, the use of 
linear mixed effects regression models, preventing listwise deletion, was applied.  
 
 
In Study III, the impact of dental treatment with dental polymer-based fillings during 
pregnancy on negative birth outcomes was investigated. When analyzing the 
association between a set of predictors and binary outcomes, logistic regression is a 
standard choice. Analysis with logistic regression allows inclusion of covariates in 
order to control for possible confounders (i.e. variables associated both with the 





The results from Study I provided weak evidence indicating that existing dental 




leaching. Although the composite group had marginally elevated levels of 
unconjugated BPA in saliva compared to the comparison group, the levels were very 
low and the difference between the groups was small.  
Almost all detected BPA in saliva was in the unconjugated form. Conjugated BPA 
was generally not found. This indicates that the BPA detected in saliva is from local 
exposure (e.g. released from the polymer-based fillings). It could be hypothesized 
that salivary BPA could be derived from blood, but this theory is unlikely because 
BPA from blood most probably would be in the conjugated form (77, 137). 
The estimated mean value of unconjugated BPA in the composite group (0.12 ng/ml) 
corresponded well to the estimated mean salivary BPA concentration detected at 
baseline (before placement of dental polymer-based fillings) in Study II (0.11 ng/ml). 
In other studies assessing salivary BPA concentrations prior to placement of dental 
polymer-based material, slightly higher estimated mean levels were reported (range 
0.22–1.0 ng/ml) (28, 130, 137, 138, 146-148). However, in the majority of studies, no 
restrictions of food or drink intake prior to sampling were described. In the present 
study, intake of breakfast showed a statistically significant effect on the salivary BPA 
level. This finding indicates that oral exposure to other sources of BPA, even though 
ingested more than 2 hours before sampling, might influence the BPA levels in saliva 
and thus pose potential misclassification bias. However, as discussed in section 




The main finding in Study II was the significant increase in the BPA concentration in 
saliva directly after treatment with a dental polymer-based restorative material. The 
increase was followed by an exponential decrease, but the levels remained 




concentration was only slightly elevated compared to the baseline levels. This time-
course of salivary BPA concentration after placement of dental polymer-based 
materials is in accordance with other studies (28, 137, 146, 148, 149). The pattern 
indicates that the main exposure to BPA from dental polymer-based filling materials 
is limited to a short period after placement. The study revealed no change in urinary 
BPA levels after placement of polymer-based restorations.  
Over the last few decades, several studies have been conducted to assess the amounts 
of BPA in saliva and urine after placement of dental polymer-based materials (28, 
146-148). However, as discussed in Paper II, the types, brands and application modes 
differ among the materials tested. Moreover, there are wide differences regarding 
sample size, number and extent of tooth surfaces filled, sampling procedures, and 
laboratory methods between studies. Another issue is that relevant details in treatment 
and sampling procedures as well as the LOD, are not always presented by the authors. 
Thus, quantitative comparison between studies has been considered impossible (150).  
The mean BPA concentration detected 10 minutes after treatment was higher than 
expected. The level was comparable with previously reported salivary BPA 
concentrations detected after placement of bis-DMA-based dental fissure sealants 
(137, 149). These studies measured salivary BPA concentrations directly after (149) 
and 1 to 3 hours after (137) treatment, and the detected values were in the range of 
0.3–2.8 ppm and 5.8–105.6 ppb, respectively. The first in vivo study showing the 
implications of BPA release from dental polymer-based filling materials was 
published by Olea et al. in 1996 (44). The authors reported cumulative salivary BPA 
concentrations 1 hour after sealant placement, that were approximately 100 times 
higher than the concentrations detected directly after treatment in the present study. 
However, the reliability of the analytical methods used in the Olea study have been 
questioned (59), and the levels have not been confirmed by later studies. Other 
researchers, evaluating the release of BPA after placement of bis-GMA-based dental 




148), have presented salivary BPA concentrations considerably lower than the levels 
detected in the present study.  
 
It has been reported that use of rubber dam during placement of dental polymer-based 
materials might reduce the increase of salivary BPA concentration directly after 
treatment (28). However, although maintaining a “dry field” is important when 
performing moisture-sensitive techniques, like placements of polymer-based 
restorations, the results from studies indicate that most dentists in non-academic 
clinical practice do not use rubber dam isolation during operative dentistry 
procedures (151, 152). In the present study, the purpose was to perform the dental 
treatment according to common clinical procedures. Thus, rubber dam was not used. 
Moreover, in order to detect the maximum BPA exposure after treatment, the 
participants were not allowed to rinse their mouth with water between filling 
placement and the subsequent saliva sampling. As reported by Sasaki et al., gargling 
water for 30 seconds after placement of polymer-based material might decrease 
salivary BPA concentrations to nearly baseline levels (130). Thus, it is plausible that 
methodological issues could have influenced the salivary BPA concentrations 
detected 10 minutes after treatment in the present study. 
Further analyses showed statistically significant associations between the surface area 
of the placed fillings, expressed as number of filling points, and the salivary BPA 
concentration detected 24 hours and 1 week after treatment. These findings support 
results from other studies (153, 154) and may indicate a leakage from the free 
(exposed) surfaces of the fillings due to impurities in the monomer used. It could be 
expected that BPA leakage from the oxygen-inhibited layer on each filling surface 
could be associatied to the number of filling points in the samples collected directly 
after treatment. However, the BPA concentrations detected 10 minutes and 1 hour 
after placement did not show such an association. One possible explanation could be 
that factors with no correlations to the filling points (e.g. surplus material after 




BPA concentration up to 1 hour after treatment. It cannot be excluded that use of 
rubber dam during the filling placement procedure, as well as rinsing the mouth after 
treatment, would have reduced the BPA exposure from these sources and thus would 
have strengthened the association between the number of filling points and salivary 
BPA concentration detected 10 minutes and 1 hour after placement.  
The analyses did not identify significant associations between the amounts (weight in 
grams) of dental material placed and salivary BPA levels. This confirms previous 
findings in the literature and might be due to the observation period in the present 
study, which was too short to observe degradation and subsequent release of unbound 
compounds trapped in the polymer network (5).  
The salivary BPA concentrations detected 10 minutes after treatment were high, and 
it could be expected that these levels could have been reflected in the subsequent 
urinary BPA concentrations. However, the urinary BPA level did not appear to be 
associated with the dental treatment. Neither the first posttreatment urine samples, 
collected 1 hour after treatment, nor the samples collected 24 hours and 1 week after 
treatment showed significant increases in BPA concentrations compared with 
baseline levels.  
The BPA concentration in urine reflects the absorbed dose of BPA (73). As for saliva, 
it could be speculated as to whether the elevated urinary concentrations at 1 hour 
(146, 148) and 24 hours (28, 146-148, 155) after treatment reported in other studies 
might have been influenced by food intake.  
The BPA concentrations in urine vary over time with exposure from the diet and 
other sources and exposure routes (54, 65, 66). Given that most of BPA is eliminated 
in urine after 5 to 7 hours (77), it is not unreasonable that 10 hour’s fasting might 
decrease the BPA exposure, and thus decrease the urinary BPA level. Thus, a 




been sufficient to compensate for a lack of exposure from food and drink 
consumption.  
Moreover, saliva sampling immediately after treatment might have considerably 
reduced the amount of BPA, that otherwise would have been absorbed, metabolized 
in the liver, and excreted via the urine (146). Furthermore, studies using single 
controlled doses of isotopically labeled BPA have indicated that following oral 
administration in adult humans, approximately half of the administered dose was 
eliminated in urine 1–3 hours after ingestion, and by 24 hours the urinary elimination 
was almost complete (64, 73). Thus, it could be speculated that the times chosen for 
posttreatment urine sampling in the present study were not the ideal time points for 
detecting levels of BPA after dental treatment. It is possible that collection of urine at 
later time points (e.g. 2 and 3 hours after treatment) could have been more useful for 
detecting BPA in the samples.  
Two participants showed higher BPA levels in urine compared to the other subjects 
(Figure 16). Both of them were among five participants who handled receipts at 
work. Looking at these five as a group, there was considerable between and within-
subject variability. However, as also found by Thayer et al. (66), average BPA levels 
were elevated. Thus, thermal paper could have been one source of exposure.  
 
 
This study revealed no increased risk of any of the following adverse birth outcomes 
– stillbirth, preterm birth, malformations, and low or high birth weight – among 
women who had white fillings placed during pregnancy. Gender-specific analyses 
showed generally similar results as when girls and boys were analyzed together.  
This study might represent the very first to investigate potential associations between 
dental polymer-based fillings placed during pregnancy and birth outcomes. In a study 




outcomes and use of anesthetic during nonsurgical periodontal treatment, treatment 
including temporary and permanent restorations, endodontic therapy, or extractions 
were found (156). However, in their study a selected sample of pregnant women 
diagnosed with periodontitis was examined. Moreover, the type of restorative 
materials, whether temporary, amalgam, or tooth-colored, was not recorded. Thus, 
although their findings are in agreement with the results described in Paper III, the 




The results presented in this thesis suggest that treatment with dental polymer-based 
restorative materials might contribute to BPA exposure in humans. However, the 
exposure appears to be relatively short and transient. Women participating in MoBa 
who had dental polymer-based restorations (white fillings) placed during pregnancy 
had no increased risk for adverse birth outcomes compared with women who did not 
consult a dentist during pregnancy.   
The daily dose of BPA from dental polymer-based restorative materials is probably 
relatively low compared with the total exposure from food and other sources and far 
below the current reference limit of Tolerable Daily Intake in Europe (i.e. 4 
micrograms per kg bodyweight per day) (95). However, the biological effects of BPA 
have been reported to occur even within the range of the detection limits of most 
analytical procedures, and its influence on tissues might show a nonmonotonic dose 
response curve (85). Moreover, dental polymer-based materials cannot be considered 
on their own, but rather they must be added to other sources of BPA to which patients 
are exposed to on a daily basis. Exposure to BPA during developmental stages of life, 
such as prenatal life, infancy, and early childhood might be of particular concern 
(106-108). Fetuses and neonates might have lower capability to metabolize and 




negative health effects (109). In this context, it should be recognized that another 
synthetic estrogen, diethylstilbestrol (DES), which was commercialized during the 
1940s, was found to be the causative factor to the higher incidence of 
adenocarcinomas of the vagina and cervix in daughters of women treated with the 
hormone during pregnancy (49).  
Ideally, dental polymer-based restorative materials should be produced without 
substances having potential adverse effects. However, products presented as BPA-
free have also shown estrogenic activity (157). As a guide to clinicians, safety data 
sheets should present essential information to identify potential harmful constituents 
in a material. However, studies have shown that data are often incomplete (29, 39, 
158). It is hoped that new regulations and an updated ISO-4049 standard (2019) 
(https://www.iso.org/standard/67596.html) will force manufacturers to provide more 
complete information about the substances in their products. 
Nevertheless, the benefit of dental polymer-based restorative material for oral health 
is well established, and these materials have become the first choice for restorative 
dental treatment (1). Given an extensive use of dental polymer-based materials, 
clinical procedures, limiting the release of BPA and other substances into the oral 
cavity after placement of such materials should be provided. Obviously, it is 
important to follow the manufacturers’ instructions with regard to indications and 
handling procedures, including optimal polymerization. Use of rubber dam during 
insertion and grinding/finishing of the material might reduce the potential exposure 
(28). Moreover, rinsing with water for 30 seconds directly after treatment might 







In line with the specific aims of this thesis, the following main conclusions were 
drawn: 
 
 There was some evidence that presence of dental polymer-based restorative 
fillings may be associated with slightly increased concentration of 
unconjugated BPA in saliva. 
 
 The contribution from pre-existing dental polymer-based fillings to the total 
BPA exposure seemed to be low.  
 
 Placement of dental polymer-based restorative materials might cause a 
substantial, short, and transient increase in salivary BPA concentration after 
treatment.  
 
 There was no evidence that treatment with dental polymer-based restorative 
material was associated with increased BPA level in urine.  
 
 The placement of dental polymer-based fillings (white fillings) during 
pregnancy was not associated with adverse birth outcomes including stillbirth, 






Due to their beneficial uses, dental polymer-based materials will continue to be an 
important contributor to restorative dental treatment. The results from the present 
work confirmed that these materials have the potential to release BPA immediately 
after placement. It is not likely that the manufacturers in the near future will be able 
to produce dental polymer-based restorative materials without any potential side 
effects. Thus, until further notice care must be taken to reduce exposure to potentially 
hazardous substances during and after dental treatment. Even though the risk for 
adverse effects might be very low, the precautionary principle (https://eur-
lex.europa.eu/legal-content) could justify the implementation of preventive clinical 
procedures in clinical guidelines, especially regarding young children, and pregnant 
woman. 
 
Future experiments should include the use of rubber dam and should allow 
participants to rinse their mouth after placement in order to reduce BPA in saliva 
directly after treatment. To obtain a more representative measure of systemic BPA 
exposure, saliva sampling should be avoided before urine collection. Furthermore, to 
monitor BPA concentration as a function of time, cumulative sampling of urine 1–6 
hours after treatment should be considered. 
 
With regard to potential adverse effects after placement of dental polymer-based 
materials during pregnancy, it might be interesting to design a case-control study with 
access to the dental records of the pregnant women. In this way, birth outcomes could 
be related to the exact dental history, including detailed information on type of 
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The aim of this study was to quantify bisphenol A (BPA) concentrations in saliva and urine 
before and after treatment with dental polymer-based restorative materials to assess if 
placement of this material is associated with increased BPA levels in saliva and urine. Twenty 
individuals in need of at least one dental restoration with polymer-based restorative material 
were included in this study. The participants were instructed to abstain from eating, drinking, 
and brushing their teeth for at least 10 hours prior to sampling. Saliva and urine were 
collected before and 10 minutes (saliva only), 1 hour, 24 hours, and 1 week after treatment. 
Samples were stored at −80°C before analyses. BPA in saliva and urine was determined with 
liquid chromatography/mass spectrometry. Linear mixed effects regression models were used 
for statistical analyses. There was a statistically significant increase of salivary BPA 
concentration directly after placement of the dental polymer-based restorations. Following 
placement, the concentration of BPA decreased exponentially with time. One week after 
treatment the BPA level in saliva was only marginally higher than before treatment. In urine, 







Bisphenol A (BPA, CAS no. 80-05-7), is a synthetic chemical substance, produced in large 
quantities and widely used in the production of polycarbonate plastics, epoxy resins, dental 
monomers, thermal paper, and numerous other products (1). BPA is known as an endocrine 
disruptor with the ability to interfere with and mimic estrogenic hormones (2-4). Concern has 
been raised about low level-exposure to BPA and the possible association with adverse health 
effects. In vitro and animal studies have linked BPA exposure to a variety of negative 
outcomes (5). In several epidemiological studies, BPA levels in human populations have been 
associated with reproductive abnormalities, adverse developmental effects, metabolic disease, 
and breast cancer among other health conditions (6-8). Although these findings are 
controversial (9), the current opinion of risk assessment agencies, such as the European Food 
Safety Authority (EFSA), is that negative health effects from BPA exposure could not be 
excluded (10). Of greatest concern is potential exposure during vulnerable periods like fetal 
and early postnatal development (4). In humans, the free (unconjugated) estrogenic form of 
BPA generally is conjugated to a nonestrogenic form via “the first pass metabolism” in the 
liver and eliminated in urine (11). However, the ability to metabolize and excrete BPA from 
the body may not be fully developed in the fetus and the neonate (12). In January 2015, the 
EFSA revised the recommended limit of “tolerable daily intake” of BPA from 50 to 4 µg/kg 
of bodyweight per day (10) and in December 2017 the European Chemicals Agency 
reclassified BPA as a chemical of very high concern (13). In November 2018, a working 
group from the EFSA started re-evaluating the potential hazards of BPA in food based on 
studies and data published after 2012. This new assessment is expected to be completed in 
2020 (https://www.efsa.europa.eu/en/press/news/180904, downloaded 22.02.2019).   
There is wide interest in the sources of BPA exposure. The primary source of human exposure 
is assumed to be through the diet because BPA can leach into the food and beverages from 
containers made of polycarbonate plastic or lined with epoxy resin coatings (1, 14, 15). 
However, results from studies have indicated human exposure also from numerous nondietary 
sources, including dust and indoor air, thermal paper, cosmetics, and dental materials (1, 10, 
15, 16).   
In dentistry, BPA is used as a raw material in the synthesis of several resin monomers and 
may be found as an impurity in dental materials (17). The most frequently used monomers 
synthesized from BPA include bisphenol A glycidyl methacrylate (Bis-GMA, CAS no. 1565-
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94-2), bisphenol A ethoxylate dimethacrylate (Bis-EMA, CAS no. 41637-38-1), and 
bisphenol A dimethacrylate (Bis-DMA, CAS no. 3253-39-2) (18, 19). It has been shown that 
bis-DMA-based materials, such as Delton LC fissure sealant, may release BPA as a result of 
hydrolysis at the ester bond (20). Bis-GMA-based materials, which typically comprise 
restorative materials, do not undergo this form of biodegradation because its ether bond is 
resistant to hydrolysis (20-24). Several in vitro and some in vivo studies have focused on BPA 
leakage from dental polymer-based filling materials and have attempted to quantify the 
amounts detected in different solutions or biological media (17, 19, 25-30). However, 
probably because of differences in the materials examined and the methodological 
approaches, the amounts reported are diverging (19, 31). Moreover, exposure from other 
sources, e.g., participants’ diet and its contribution to the BPA concentration in biological 
samples (e.g. urine), has not thoroughly been considered in previous clinical studies.  
The aim of this study was to quantify BPA concentrations in saliva and urine before and after 
treatment with dental polymer-based restorative materials to assess if placement of these 
materials is associated with increased BPA levels in saliva and urine.  
 
Material and methods  
Study population 
Patients in need of at least one dental restoration of two or more dental surfaces with a 
polymer-based restorative material were informed about the study by their dental hygienist or 
dentist at their regular dental examination at two public dental clinics in Bergen, Norway. 
Patients who chose to participate were given written information about the study for perusal at 
home. Individuals with removable dentures, dental splints, and those who currently were 
undergoing orthodontic treatment were excluded. Smokers, snuff users, and drug abusers 
were also excluded. We did not include individuals who had received polymer-based dental 
fillings during the previous 3 months, dental students, and dental health workers. Twenty 
volunteers, between 16 and 40 years of age, without any known diseases or medications at the 
time of the study, were included in the study from January 2016 to November 2017. All 





Ethical approval  
All procedures involving human participants were performed in accordance with the ethical 
standards of the 1964 Helsinki declaration and its later amendments or comparable ethical 
standards. The study protocol was reviewed and approved by The Regional Committee for 
Medical Research Ethics, South-East Norway (reference number 2014/1529). The study is 
registered at ClinicalTrials.gov, number NCT02575118.  
Dental treatment procedures 
One dentist (TLLB) recorded the number of tooth surfaces previously filled with tooth-
colored restorative materials. The same dentist (TLLB) provided the dental treatment at one 
public dental clinic in Bergen, Norway. The treatment was performed according to 
standardized procedures and materials used at the clinic. Local anesthesia (Xylocain Dental 
adrenalin, Dentsply, Weybridge, England) was used in 19 of the participants; one participant 
preferred treatment without anesthesia. Cavity preparations were performed with diamond 
burs (Horico, Berlin, Germany) and round steel burs (Meisinger, Neuss, Germany). Cotton 
rolls and low-volume evacuator equipment (Hygoformic Saliva Ejector, Orsing, Helsingborg, 
Sweden) were used for moisture control. High-volume evacuator equipment (Hygovac 
aspirator tube, Orsing, Helsingborg, Sweden) was used during cavity preparations, etching, 
bonding and finishing procedures.  Rubber dam isolation was not used. Contoured anatomical 
steel matrices (Polydentia SA, Mezzovico, Switzerland) were used to support and shape the 
restorations in premolars/molars and transparent curved strips (Hawe Neos, Kerr, Orange, 
California, USA) were used in front teeth. Dental approximal wooden wedges (Hawe 
Sycamore, Kerr, Orange, California, USA) were used in all cases. Etching with 37% 
phosphoric acid (ANA Etching Gel 37%, Directa, Upplands Väsby, Sweden) was performed 
according to the principles of the total etch technique (32).  A two-part primer adhesive 
system (OptiBond FL, Kerr, Orange, California, USA) was used as the bonding agent. The 
cavities were restored with a widely used filling material (Tetric EvoCeram, 0.2 g compules, 
Color A2, LOT 14504, Ivoclar Vivadent AG, Schaan, Liechtenstein), tested to be assured it 
was bis-GMA-based. The bonding procedure and the application of the filling material were 
carried out according to the manufacturers’ instructions. For each participant a new compule 
with filling material was used. The material was applied in incremental layers of <2.0 mm and 
each layer was cured for 20-30 seconds. Care was taken to avoid application of excessive 
amounts of material. Any surplus was removed and put back into the compule. Each compule 
was weighed before and after treatment, using an analytical balance (AG204 DeltaRange, 
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Mettler Toledo, Greifensee, Switzerland). The amount (weight in gram) of polymer-based 
material used in each participant was estimated by the difference between the two 
measurements. The curing lamp (Satelec Mini LED, Aceton, Meriganac, France) emitted a 
600 to 700-mW/cm2 light intensity at a range from 440 to 460-nm. The lamp was controlled 
prior to each treatment using a hand-held curing radiometer (Model 100, Dementron, Kerr, 
Danbury, Connecticut USA). After curing, the fillings were polished according to standard 
procedures using diamond polishing burs (FossViking, Fetsund, Norway), polishing disks 
(Sof-Lex XT Pop, 3M Espe, St. Paul, Minnesota USA) and silicone polishers (Identoflex 
Composite Polisher, Kerr, Bioggio, Switzerland).  
The restorations differed in size depending on the tooth size and the extent of the prepared 
lesion. To adjust for differences, each filling surface was given scores from 1 to 3, depending 
on its area (33). Small restorations were given the lowest score of 1. Restorations of 
intermediate size, typically the approximal or occlusal surfaces of Class II restorations in 
premolars, were given a score of 2. The highest score, 3, was used for molars to denote 
restorations extending over the total occlusal fissure pattern or over the approximal surface of 
Class II restorations. The scores for all polymer-based filling surfaces treated in each patient 
were summed and yielded the variable “filling points”. The tooth surfaces treated and the 
estimated “filling points” were recorded.  
Sample collection 
All treatment sessions were scheduled in the morning before 9 am. Prior to the treatment, the 
participants were asked about their dental hygiene habits and if they had work that involved 
handling of receipts (thermal paper). Each participant provided a total of five saliva samples 
and four urine samples. The first saliva and urine samples 
were collected immediately before treatment, after a 10-h fast. Sampling of a second saliva 
sample was started 10 min after placement of the polymer-based fillings, and subsequent 
saliva and urine samples were collected 1 h, 24 h, and 1 wk after placement of the fillings 
(Fig. 1). On each day of sampling, the participants also answered questions regarding 
consumption of canned and microwaved food during the previous week and within the 
previous 24 hours. To reduce the exposure from other potential BPA sources, the participants 
were instructed to abstain from eating, drinking, and brushing their teeth for at least 10 hours 
prior to sampling. Only tap-water was allowed for drinking. The participants were asked not 
to use lip balm or lipstick during the same period. To identify possible contamination during 
sampling, transport and storage, field blanks were collected using ultra-pure water (Synergy 
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Water Purification Systems, Millipore, Billerica, Massachusetts, USA) instead of saliva and 
urine. The field blanks were treated like the biological samples in all aspects. 
For saliva sampling, the participants were sitting in a relaxed position in the dental unit chair. 
They were instructed to spit in the dental unit sink, but rinsing was not allowed. Immediately 
after, they were instructed to do active tongue and cheek movements for 60 seconds and then 
spit the accumulated saliva into a polypropylene tube (15 ml, order number 62.554.001, 
Sarstedt AG & Co, Nümbrecht, Germany) until about 2 ml of saliva were sampled. To avoid 
contamination from the ambient air, they were asked to put the cap back on the tube between 
each spit. The sampling time was recorded. 
Since the first morning urine void should not be collected, the participants were instructed to 
empty their bladder in the morning at home before entering the clinic. Urine specimens were 
collected in 100-ml polypropylene cups (order number 75.562.300, Sarstedt AG & Co, 
Nümbrecht, Germany) and aliquots were transferred into 15-ml polypropylene tubes. 
Immediately after collection, the samples were refrigerated (at 4°C) and within the same day 
stored frozen at −80°C until they were sent for analysis.  
Determination of BPA in saliva and urine  
Urine and saliva samples were analyzed at the laboratory of the Division of Occupational and 
Environmental Medicine at Lund University, Sweden, using liquid chromatography-triple 
quadrupole mass spectrometry (LC/MS/MS; QTRAP 5500; AB Sciex, Foster City, California, 
USA). Saliva samples were analyzed using a method described by BERGE et al (34) and urine 
samples were analyzed using a modified method described by GYLLENHAMMAR et al (35). 
Briefly, for the determination of total BPA in saliva, aliquots of 100 μl were digested with 
glucuronidase added with isotopically labeled internal standard for BPA (D16-BPA) and 
proteins were precipitated using acetonitrile. Free (unconjugated) BPA in saliva was 
determined without using glucuronidase. For the analysis of total BPA in urine samples, 
aliquots of 200 μl were digested with glucuronidase added with D16-BPA. The concentration 
of BPA in urine was adjusted for urinary density (36). Two different in-house prepared 
quality control (QC) samples and chemical blanks were analyzed in the analytical batches. 
The limit of detection (LOD) was determined to be 0.1 ng/ml. The method had acceptable 
between-day and within-run precision. The laboratory used is a European reference laboratory 
for BPA in urine (http://www.eu-bm.info/democophes) and a reference laboratory for BPA in 
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urine in the Erlangen Round Robin inter-laboratory control program. A detailed description of 
the analytical method is given in the Supplemental File. 
Statistical method 
Descriptive statistics were presented as mean, minimum, maximum values, and standard 
deviation (SD) for continuous variables, and as frequencies for categorical variables. For the 
analyses of repeated measures of the saliva and urine samples, linear mixed effects regression 
models were applied. In the mixed effects model, the repeated nature of the measurements of 
the data were accounted for using the patient ID, entered as a random factor, with an 
additional factor for time to account for the difference in variation (standard deviation) over 
time.  
Time for the measurements was entered as a categorical variable in the models, comparing the 
succeeding measurements with the baseline (before treatment) measure. All available data, 
and hence data for participants with missing observations at some time points, were included 
in the model.  
The decrease over time of the mean posttreatment BPA concentration in saliva was described 
using the equation: Y = aXb, where Y is the BPA concentration and X is time. The equation 
was estimated by applying mixed effects regression on a log transform of the equation (which 
transforms the equation to a linear model). 
For the descriptive statistics, SPSS (IBM SPSS, Version 25, NY, USA) was applied, while for 
the mixed effect analyses Stata (version 15, TX, USA) was applied.  
Values below the limit of detection (LOD) were set to one half of the LOD in the statistical 
analysis (37). P-values less than 0.05 were considered statistically significant.  
 
Results  
Background and dental treatment characteristics 
Background characteristics of the participants are shown in Table 1. Data regarding dental 
hygiene habits and consumption of canned and microwaved food are listed in Table 2. Details 
regarding dental treatment are shown in Table 3. Three of the participants attended the study 
without having any pre-existing polymer-based dental fillings and nine had polymer-based 
fillings removed during treatment.  
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Concentration of BPA in saliva 
The saliva samples collected 10 minutes after treatment showed a statistically significant 
increase in BPA levels compared with the pretreatment samples. The concentrations remained 
significantly elevated 1 hour, 24 hours and 1 week after placement (Table 4; Fig. 2). After the 
immediate posttreatment increase, the concentration of BPA in saliva (Y; ng/ml) decreased 
exponentially. We estimated the relationship between the decrease and time (X; hours) to be 
Y=54.2X-1.12 (Fig. 3). In saliva no conjugated BPA was detected. Pretreatment levels of BPA 
in saliva were low, and the mean value was estimated to be 0.11 ng/ml (Table 4). Before 
treatment, 11 of 20 (55%) participants had salivary BPA levels below the detection limit (0.1 
ng/ml). In one saliva sample collected before treatment the BPA concentration was more than 
100 times higher (11.6 ng/ml) than the mean value and more than 100 standard deviations 
from the mean of the remaining 19 samples. This saliva sample was excluded from the 
statistical analysis because of probable contamination. One participant had breakfast before 
the sampling 1 week after treatment and thus the samples collected this day from this 
participant were not included in the statistical analysis.  
The levels of BPA concentrations in saliva were confirmed by analyzing nine samples using 
LC/MS/MS at an independent laboratory (Nordic Institute of Dental Materials, Oslo, 
Norway). These samples were selected to represent the full range of the values from the 
laboratory in Lund. The interclass correlation was high (0.91; 95% CI: 0.72–0.98), which 
indicates high agreement between the measurements.  
Secondary explorative analysis showed that the number of filling points was 
associated with the BPA levels in saliva 24 hours (p=0.011) and 1 week (p=0.029) 
after treatment. However, neither number of filling surfaces nor the amount (weight) 
of dental polymer-based material placed was associated with the salivary BPA 
concentration at any time point (all p>0.05). Moreover, there were no statistically 
significant associations between the other covariates tested and the salivary BPA 
levels at the different time points (see Tables 1, 2, and 3 for tested variables).  
Concentration of BPA in urine 
Table 4 presents density adjusted concentrations of BPA in urine before and after treatment. 
Before treatment, 19 of 20 (95%) participants had detectable BPA levels in their urine. There 
were no statistically significant differences between urinary BPA levels before and after 
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placement of the dental polymer-based restorations (Table 4; Fig. 4). BPA levels in the urine 
samples collected 1 hour after treatment did not show a statistically significant association 
with the BPA level in the saliva samples collected within 10 minutes after treatment (Data not 
shown). 
Fig. 4, presenting the urinary BPA levels over time, illustrates that two of the participants 
showed considerably higher BPA levels than the others. One of these participants had higher 
levels at all time points, while the other only had an elevated BPA concentration after one 
week. These participants were identified as two of five participants handling cash register 
receipts at work. The participant with highest levels in urine was also the one with the highest 
levels of BPA in saliva at all time points. Using receipts as a group variable (yes; n=5 / no; 
n=15) we found an overall elevated average level of urinary BPA in the group handling 
receipts (p=0.031, mean difference 0.83 ng/ml; 95% CI: 0.08-1.57). 
Regression models testing additional potential factors that could contribute to the BPA 
concentration in urine (see Tables 1, 2, and 3 for tested variables) did not show a statistically 
significant influence at any time point (all p>0.05). 
All field blanks had BPA concentrations below the detection limit. 
 
Discussion 
There was a considerable increase in the BPA concentration in saliva directly after placement 
of a dental polymer-based dental restorative material. The concentration of BPA then 
decreased exponentially with time. One week after treatment the concentration of BPA in 
saliva was only marginally higher than before treatment. This is in agreement with the results 
from other studies of BPA leakage from existing polymer-based fillings (29, 34). The time-
course of the salivary BPA concentration after treatment is in accordance with other studies 
and supports a plausible pattern, which suggests that the main exposure to BPA from 
polymer-based dental filling materials is limited to a short period after placement (21, 26, 38, 
39). In urine, no change of the BPA concentration was detected after treatment.  
Over the last two decades, the amounts of BPA in saliva and urine after placement of dental 
polymer-based materials have been examined in several studies (26, 28, 30, 39). However, 
there are wide differences in the materials tested regarding composition, brands, and 
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application modes. Moreover, the size and number of tooth surfaces filled, sampling 
procedures, measurement time points and intervals, analytical methods, sensitivity of 
methods, and detection limits differ between studies. These differences may account for 
diverging results, which make the comparison between studies and calculations of the actual 
amount released difficult (19, 31). KLOUKOS et al. (31), searching the literature to assess the 
short- and long-term release of BPA in human tissues after treatment with dental sealants, 
concluded that only qualitative evaluation may be performed. 
In the present study, the mean BPA concentration detected in saliva immediately after 
treatment was higher than expected. Our results are comparable with previous studies 
assessing salivary BPA concentrations directly after (21) and 1 to 3 hours after (38) placement 
of a bis-DMA-based dental fissure sealant (Delton LC). The range in BPA concentrations 
from these studies was 0.3–2.8 ppm and 5.8–105.6 ppb, respectively. OLEA et al. (25) 
reported that the cumulative salivary BPA concentration 1 hour after sealant placement was 
approximately 100 times higher than the BPA concentration detected directly after treatment 
in our study. However, the reliability of the analytical method used by OLEA et al. has been 
questioned (22) and the levels have not been confirmed by later studies. Other authors have 
evaluated the release of BPA in saliva after placement of bis-GMA-based dental materials 
used as restoratives (26, 29, 40, 41), and in orthodontic treatment, bonding lingual retainers 
(28), or brackets (30, 42). Compared with the salivary BPA levels reported in these studies, 
our levels are considerably higher.  
The potential of dental polymer-based restorative materials to release BPA may differ 
depending on the BPA-derivatives included in the material. Because of the hydrolysis of bis-
DMA, the BPA concentration in saliva collected directly after treatment with bis-DMA-based 
materials is expected to be higher than the amount of BPA found in salivary samples collected 
directly after placement of bis-GMA-based material (22, 24). However, the wide divergence 
in the salivary BPA concentration reported may in part have other explanations. The source of 
BPA in bis-GMA-based materials includes residual BPA present in the raw materials used in 
the manufacturing process (43). The amount of BPA left from the synthesis of bis-GMA may 
vary between different producers. A notable batch to batch variation could also be expected if 
different raw materials are used (43).  
The release of components from dental polymer-based materials after curing could be a 
consequence of incomplete polymerization (44). During the polymerization process most of 
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the monomers should be converted into polymers to form a polymer network. However, the 
degree of conversion is reported never to be complete (45, 46). The extent to which 
monomers are converted may be influenced by several factors including the curing time, the 
light intensity, the composition of the polymer-based material and the thickness of the 
incremental layer (47). In the present study, the dental polymer-based material was placed in 
layers and cured according to the manufacturer’s instructions. No association was found 
between the amount (weight) of material placed and salivary BPA concentration. This finding 
is in agreement with other studies and may be explained by the observation period used in the 
present study, which was too short to allow degradation and subsequent release of unbound 
compounds trapped in the polymer network (17). However, the exposure of materials to air 
inhibits polymerization and leads to a thin, liquid layer on the filling surface (48, 49). From 
this layer uncured components have the potential to leak immediately into the oral 
environment for a short time (17). Some studies have indicated that the BPA release from 
dental polymer-based fillings depends on the surface area that is exposed (50, 51). Our study 
found no association between the surface area of the polymer-based material placed and the 
salivary BPA levels immediately after and 1 hour after treatment. However, 24 hours and 1 
week after treatment, the BPA concentration was associated with the number of filling points. 
Moisture control during restorative dental treatment may include cotton rolls and a rubber 
dam combined with a saliva ejector. It has been reported that the increase in salivary BPA 
concentrations directly after placement of dental polymer-based material may be lower when 
a rubber dam is used (26); however, studies indicate that most dentists do not use rubber dam 
isolation during operative dentistry procedures (52, 53). We expected the leakage of BPA 
from newly placed polymer-based fillings to be low, so, in an effort to perform the most 
commonly used clinical procedures and detect the maximum BPA released after treatment, a 
rubber dam was not used during treatment in our study. Immediately after treatment, the 
participants were instructed to spit once in the unit sink. They then performed cheek and 
tongue movements and consecutively collected the accumulated saliva in tubes. Neither 
rinsing nor gargling was allowed before saliva sampling. Thus, the saliva samples collected 
immediately after treatment in our study may include BPA exposure from the uncured layer 
as well as surplus of material left over from the grinding and polishing procedure. Probably 
the association between surface area (filling points) and BPA concentration immediately after 
treatment would have been stronger if gargling had been permitted. Rinsing the mouth with 
water for 30 seconds after polymer-based filling placement has been shown to decrease the 
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BPA concentration in saliva to nearly baseline levels (41). In some studies, it was not reported 
whether the participants were instructed to rinse their mouth before sampling. Moreover, the 
time interval reflecting “immediately after treatment” may vary from 5 to 60 minutes across 
studies (26, 28, 29). Thus, the varied sampling procedures could influence the differences in 
the BPA concentrations detected and complicate estimation of the amount of BPA released 
immediately after treatment.   
Clinical studies examining saliva concentration of leachable chemicals from dental polymer-
based materials show generally wide variations between participants and the relative standard 
deviation is usually high (25, 41, 54). Thus, the homogeneity and representativeness of the 
saliva samples could be questioned (55).  
In the present study the participants were instructed to refrain from food and beverage intake 
10 hours before sample collections. Urine samples were collected prior to treatment and 1 
hour, 24 hours and 1 week after treatment. The salivary BPA concentrations detected 
immediately after treatment were high and could be expected to be reflected in the subsequent 
urinary BPA concentrations. However, neither the first posttreatment urine samples, collected 
1 hour after treatment, nor any other posttreatment samples showed significant increases in 
BPA concentrations compared with pretreatment levels. This is in contrast to the findings by 
JOSKOW et al (39), which indicated that urinary BPA levels were highest 1 hour after sealant 
placement. Over time, there is a large variation of BPA in urine (56), and intake of food has a 
considerable influence on the concentration of BPA in urine (57). Thus, it could be speculated 
that the elevated urinary concentrations 1 hour after treatment reported in other studies may 
have been influenced by food intake before treatment. However, 10 hours of fasting may 
decrease the BPA exposure, and subsequently the urinary BPA level, and thus partly mask a 
potential increase in the urinary BPA concentration caused by the dental treatment. The BPA 
concentration in urine reflects the absorbed dose of BPA (58). Because saliva samples were 
collected immediately after treatment, we may have reduced a significant amount of BPA, 
which otherwise would have been absorbed, metabolized in the liver, and excreted via the 
urine. Thus, saliva sampling directly after treatment could have influenced the BPA 
concentrations in urine considerably (39). 
In the present study we used LC/MS/MS with an isotopically labeled internal standard (D16-
BPA) for the analysis of BPA. This is the method of choice for the determination of BPA in 
biological samples (59). Quality control samples and field blanks were analyzed together with 
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the samples of saliva and urine. In addition, a limited number of saliva samples were analyzed 
at a second laboratory and showed similar results. Thus, we evaluated the analysis to be 
reliable and the accuracy and precision acceptable for the present purpose. 
To standardize the procedures as much as possible, the dental treatment was provided by one 
dentist at one dental clinic using the same procedures for all patients. Moreover, the same 
batch of filling material was used for all fillings.  
The participants in the present study acted as their own control as reflected by pretreatment 
sampling. Including an unexposed control group would have enabled us to better interpret the 
contribution of the polymer-based material to urinary BPA levels. Although data from the 
study by JOSKOW et al. (39) indicate an increase of BPA in urine 1 hour after treatment, it is 
possible that the peak concentration of BPA in urine after exposure is between 1 and 4 hours 
(58). Thus, the sample collection at 1 hour may have been too early for detection of the 
maximum concentration of BPA in urine. 
Two participants showed significantly higher urinary BPA levels compared with the other 
participants (Fig. 4). One of them had elevated BPA levels in urine at all time points. Both 
participants handled receipts at work and consequently, thermal paper could be one source of 
exposure. Looking at the group of participants handling receipts, there were substantial 
between- and within-subject variability, but average levels were elevated, as was also found 
by THAYER et al (60).   
There may be considerable differences regarding potential BPA exposure depending on 
materials used. Because only one batch of one material was tested in this study, the detected 
amounts of BPA must be interpreted with care. Materials with less BPA contamination may 
cause lower exposure. Hence, the daily dose of BPA from dental polymer-based restorative 
materials is probably relatively low compared with the total exposure from food and other 
sources (10). However, the biologic effects of BPA have been reported to occur even within 
the range of the detection threshold of most analytical procedures, and its influence on tissues 
may show a nonmonotonic dose response curve pattern (61). This is characterized by intense 
reactivity at low levels and no response at high levels (62).  
Data on the chemical composition of dental polymer-based material from the material Safety 
Data Sheets are incomplete (19). Therefore, manufacturers should be required to provide 
more exact information about the composition of their products (19). Ideally, dental polymer-
15 
 
based materials should be produced without components having estrogenic effects. However, 
materials introduced as BPA free have also shown estrogenic activity (63). Thus, methods to 
reduce the release of BPA after placement of dental polymer-based materials should be 
provided. Using a rubber dam to control the operative field would limit the potential exposure 
(26). Moreover, rinsing with water directly after treatment should be highly recommended 
(41).  
In conclusion, the findings in this study confirm that placement of dental polymer-based 
restorative materials may cause a substantial increase in salivary BPA concentrations after 
treatment. The results indicate that the exposure to BPA is relatively short and transient. After 
1 week, the concentration of BPA in saliva was only slightly elevated compared with the 
levels before treatment. This study did not show changes in the BPA concentration in urine 
after treatment with a dental polymer-based restorative material.  
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Fig. 2. Salivary concentrations (ng/ml) of bisphenol A (BPA) among participants (individual 
patterns) before treatment (baseline) and 10 minutes, 1 hour, 24 hours and 1 week after 







Fig. 3. Concentration (ng/ml) of bisphenol A (BPA) in saliva after treatment with polymer-






Fig. 4. Urinary concentrations (ng/ml) of bisphenol A (BPA) among participants (individual 
patterns) before treatment (baseline) and 1 hour, 24 hours and 1 week after treatment with 
polymer-based filling material (n=20). 
Table 1 




 Women/Men  13/7 
Age (years) 
 Mean (SD)
1 23.4 (5.7) 
 Min
2-Max3   17 - 36 
Education (years) 
 Mean (SD) 13.8 (1.8) 
 Min-Max   10 - 17 
Daily use of chewing gum 
 Yes/No  4/16 
Daily use of toothpaste 
 Yes/No  20/0 
Use of rinsing agents 
 Yes/No  11/9 
Job handling receipts 
  Yes/No  5/15 
1 Standard deviation; 2 Minimum; 3 Maximum 
 
Table 2 
Data regarding participants’ dental hygiene habits and intake of canned and microwaved food by sampling day (n=20) 
Variables 
Day 1   Day 2 Day 8 
(Day of 
treatment) 
(24 hours after 
treatment) 
(1 week after 
treatment) 
Refrained from food and drink at least 10 hours before 
sampling 
   
 Yes/No 20/0 20/0 19/1 
Brushed teeth during the morning before sampling 
   
 Yes/No 5/15 2/18 2/18 
Use of mouth rinse before sampling 
   
 Yes/No 1/19 1/19 0/20 
Intake of canned food last 24 hours 
   
 Yes/No 4/16 2/18 4/16 
Intake of microwaved food last 24 hours 
   
 Yes/No 2/18 2/18 1/19 
Intake of canned food last week 
   
 Yes/No 13/7 NA 12/8 
Intake of microwaved food last week 
   
  Yes/No 7/13 NA 2/18 
NA: Not applicable    
 
Table 3 
Data regarding previous and current dental restorative treatment of the participants (n=20)   
Variables  Mean (SD)1 Min2 Max3 
Number of preexisting tooth-colored filling surfaces    11.8 (9.6) 0 26 
Number of preexisting tooth-colored filling points 25.7 (21.7) 0 68 
Number of polymer-based filling surfaces removed during treatment 0.70 (0.92) 0 3 
Number of polymer-based filling points removed during treatment 1.8 (2.7) 0 9 
Number of treated filling surfaces 3.7 (1.9) 2 10 
Number of treated filling points 7.7 (0.7) 4 15 
Weight of polymer-based material used (g) 0.158 (0.067) 0.065 0.309 
1 Standard deviation; 2 Minimum; 3 Maximum    
 
Table 4 
Estimated BPA concentration (ng/ml) in saliva and urine samples before and after treatment with 
polymer-based dental restorative material 
Time point N Mean (95% CI) P value 
Saliva Before treatment 19 0.11 (<LOD–0.16) Reference 
10 minutes after treatment 20 385 (205–565) < 0.001 
1 hour after treatment 20 88.2 (42.4–134) < 0.001 
24 hours after treatment 20 1.85 (0.72–2.98) 0.003 
1 week after treatment 19 0.25 (0.17–0.33) 0.002 
Urine1 Before treatment  20 1.41 (0.42–2.41) Reference 
1 hour after treatment 20 1.17 (0.18–2.16) 0.674 
24 hours after treatment 20 1.53 (0.54–2.53) 0.834 
1 week after treatment 19 1.99 (0.97–3.00) 0.321 
Limit of detection (LOD) = 0.1 ng/ml, values < 0.1 ng/ml were set to half of the LOD 
1  Density adjusted urine concentrations (1.016 g/l) 
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Abstract
Background: Tooth-coloured polymer-based dental filling materials are currently the first choice for dental
restorative treatment in many countries. However, there are some concerns about their safety. It has been shown
that substances known as endocrine disrupters, which might pass through the placental barrier, are released from
these materials within the first hours after curing. Thus, the placement of polymer-based dental fillings in pregnant
women may put the vulnerable foetus at risk. Large epidemiological studies exploring the risk of having polymer-
based dental materials placed during pregnancy are lacking. The aim of this study was to investigate the
association between the placement of polymer-based dental fillings during pregnancy and adverse birth outcomes.
Methods: This study is based on data from the large Norwegian Mother and Child Cohort Study (MoBa). The
information about dental treatment during pregnancy was obtained from questionnaires sent to the participating
women during weeks 17 and 30 of pregnancy. Reported placement of “white fillings” was used as exposure marker
for having received polymer-based dental filling materials. Only singleton births were included in the present study.
Data were linked to the Medical Birth Registry of Norway. Logistic regression models that included the mother’s
age, level of education, body mass index, parity, and smoking and alcohol consumption during pregnancy were
used to estimate the odds ratio (OR) and 95% confidence interval (CI). Different adverse birth outcomes were of
interest in the present study.
Results: Valid data were available from 90,886 pregnancies. Dentist consultation during pregnancy was reported by
33,727 women, 10,972 of whom had white fillings placed. The adjusted logistic regression models showed no
statistically significant association between having white dental fillings placed during pregnancy and stillbirth,
malformations, preterm births, and low or high birth weight.
Conclusions: In this study, women who reported white fillings placed during pregnancy had no increased risk for
adverse birth outcomes compared with women who did not consult a dentist during pregnancy. Thus, our findings
do not support the hypothesis of an association between placement of polymer-based fillings during pregnancy
and adverse birth outcomes.
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Background
Tooth-coloured polymer-based materials are the first
choice for dental restorative treatment in many coun-
tries [1, 2]. However, there are concerns about the safety
of these materials [3]. Results of in vitro and in vivo
studies have shown that substances that potentially
could lead to adverse effects in the patient are released
from these materials within 24 h after curing [4–8].
Elution may initially be due to incomplete polymerization
[9, 10] and contaminants [11, 12]. The local adverse
effects [13] caused by the leachable components are rare
[14]. However, the possibility of systemic adverse effects
could not be ruled out [15].
The elution of bisphenol A (BPA) has been of particular
concern [16]. BPA is a chemical known to be an endocrine
disruptor, mimicking oestrogen [17, 18]. Polymer-based
dental filling materials may contain BPA as an impurity
from the production process of bisphenol-A glycidyl
dimethacrylate (Bis-GMA) [8, 11, 19, 20] or, less probable,
a degradation product of monomers [12, 21, 22]. Results
from animal studies have indicated that BPA has repro-
ductive, developmental and systemic toxic effects [23, 24].
It has been shown that newly placed composite restora-
tions in humans may be associated with short-term
elevated BPA levels in both saliva and urine [4, 7].
The impact of exposure to BPA on human health
remains uncertain. However, data from the literature in-
dicate that exposure to BPA, even at relatively low doses,
could potentially result in adverse health effects [15].
Moreover, studies suggest that BPA might pass through
the placental barrier [25], and thus, maternal exposure
to BPA may offer a potential risk to the vulnerable
foetus.
Even though substances with potential toxicity are
released from dental polymer-based materials [4, 5],
studies exploring the risk of having these materials
placed during pregnancy are lacking.
The aim of the present study was to investigate
whether the placement of polymer-based dental fillings
during pregnancy is associated with adverse birth out-
comes including stillbirth, preterm birth, malformations
and low or high birth weight.
Methods
Data from the ongoing Norwegian Mother and Child
Cohort Study (MoBa), a prospective population-based
cohort study conducted by the Norwegian Institute of
Public Health, were used. From 1999 to the end of 2008,
pregnant women in Norway were invited to MoBa
through a postal invitation in connection with their first
routine ultrasound examination. The participation rate
was approximately 41%, and the cohort currently com-
prises more than 108,000 pregnancies, 114,000 children,
95,000 mothers and 75,000 fathers. Written informed
consent was obtained from each participant upon
recruitment [26, 27].
In the present study, data were gathered from two
questionnaires that were sent to the participating women
in weeks 17 and 30 of pregnancy [28]. Each woman
could participate with multiple pregnancies. Only single-
ton births were included in the present study.
Information about white fillings placed during preg-
nancy was obtained from the questionnaires sent to the
participants in week 30. Reported placement of white
fillings was used as exposure marker. The participants
reported if they had consulted a dentist during
pregnancy (“Have you been to the dentist during this
pregnancy? Yes/No”) and if so, whether they had
received white fillings (“If, yes, did the dentist put in
new white fillings? Yes/No”).
Women without valid information about dental treat-
ment during pregnancy and those with missing data on
birth outcomes were excluded, leaving a study popula-
tion that included 90,886 pregnancies (Fig. 1).
Information about gender, preterm delivery, stillbirth,
malformations, birth weight and mother’s age at delivery
was obtained from the Medical Birth Registry of Norway
(MBRN) [29]. The mother’s 11-digit unique personal
identification number assigned to every citizen in
Norway was used to link data sources. Gestational age
was based on ultrasound examination in the 17th week
of pregnancy.
Infants were classified as late preterm if they were
born between gestational week 33 and 37, and very
preterm if they were born before or during the 32nd
gestational week [30, 31]. Infants with a birth weight less
than 2500 g at birth were classified as low-birth weight
infants, and infants with a birth weight more than
4000 g were classified as high-birth weight infants [32].
Maternal body mass index (BMI; kg/m2) was calculated
from self-reported pre-pregnancy height and weight.
The BMI was categorized according to the WHO
classification [33].
Information about parity, defined as the number of
former births with a gestational age of 12 weeks or
more, was based on data reported by the mothers in the
MoBa study and from the MBRN.
Information about education, smoking habits and alco-
hol consumption during pregnancy was obtained from
the first questionnaire completed at approximately the
17th week.
The present study is based on version 8 of the
quality-assured MoBa data files. We defined dental
treatment during pregnancy as follows: participants who
did not consult a dentist during pregnancy (reference
category); participants who consulted a dentist but had
no white fillings placed; and participants who consulted
a dentist and had white fillings placed (Fig. 1).
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Infants were defined as small for gestational age (SGA)
if the weight at birth was less than the 10th percentile
for gestational age and large for gestational age (LGA) if
they were larger than the 90th percentile. Very small for
gestational age was defined as weight below the 2.5th
percentile [34].
The odds ratio (OR) with a 95% confidence interval
was calculated using logistic regression. The OR was
adjusted for maternal age (≤19, 20–24, 25–29, 30–34,
35–39, 40+ years), length of education (≤12, 13–16,
≥17 years), pre-pregnancy BMI (< 18.5, 18.5–24.9, 25.0–
29.9, 30.0–34.9, 35.0–39.9, ≥ 40 kg/m2), parity (first,
second and more), smoking during pregnancy (never,
occasionally, daily) and alcohol consumption during
pregnancy (never, less than once a week, once a week,
more than once a week).
Analyses were performed using IBM-SPSS (IBM Corp.
Released 2016. IBM SPSS Statistics for Windows,
Version 24.0, Armonk, NY, USA: IBM Corp.). p-values
less than 0.05 were considered statistically significant.
The MoBa cohort study obtained a license from the
Norwegian Data Inspectorate, and this research project
was approved by the Regional Ethics Committee for
Medical Research (REC South-East D, 2011/727).
Results
Dentist consultation during pregnancy was reported by
33,727 women, and of these, 10,972 had white fillings
placed (Fig. 1). Detailed descriptive information regard-
ing the characteristics of the participants is included in
Table 1. Of the included pregnancies, 204 (0.2%) resulted
in a stillbirth. The overall proportion of malformation
was 4.8%, and the proportion of very preterm births and
late preterm births was 0.6 and 3.8%, respectively
(Table 2).
Compared to the reference group, there was no statis-
tically significant increased risk for any adverse birth
outcomes for participants who had consulted a dentist
during pregnancy without having white fillings placed or
for those who had white fillings placed (Table 3).
Separate analyses by gender showed that girls born to
mothers who had white fillings placed during pregnancy
had an increased risk of being small for gestational age
(below the 10th percentile) compared to the reference
group. The unadjusted OR was 1.14 (95% CI 1.01–1.28;
p = 0.029) while after adjustment for potential
confounders, the OR was reduced and not statistically
significant (OR = 1.10, 95% CI 0.97–1.24; Table 3).
Boys born to mothers who received white fillings dur-
ing pregnancy had a slightly increased risk of being born
late preterm compared to the boys born in the reference
group. The unadjusted OR was 1.16 (95% CI 1.01–1.34;
p = 0.041), and the adjusted OR was 1.13 (95% CI 0.98–
1.31; p = 0.082; Table 3).
Discussion
The aim of the present study was to investigate whether
the placement of polymer-based dental fillings during
pregnancy was associated with outcomes including still-
birth, preterm delivery, malformations, and low or high
Fig. 1 Flowchart showing number of participants included in the study and the groups available for analysis
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birth weight. No evidence of an increased risk of adverse
birth outcomes after placement of white fillings during
pregnancy was found. Gender-specific analyses showed
generally similar results for girls and boys analysed
together.
The main strengths of the present study are the overall
large sample size and the large number of participants
who had white fillings placed. These large numbers
enabled us to study even rare birth outcomes. Further-
more, the prospective design of the study reduced the
risk for recall bias. Additionally, the information on
health-related and lifestyle data that was derived from
both the MBRN and the MoBa questionnaires enabled
us to control for some potential confounding factors.
To the best of our knowledge, the present study is
the first to investigate potential associations between
Table 1 Characteristics of the participants related to dental treatment during pregnancy (n = 90,886)
Did not consult a dentist Consulted a dentist,




Number of participating pregnancies, n (%) 57,159 (62.9) 22,755 (25.0) 10,972 (12.1) 90,886 (100)
Maternal age (years), n (%)
≤ 19 525 (0.9) 207 (0.9) 127 (1.2) 859 (0.9)
20–24 6056 (10.6) 1767 (7.8) 1195 (10.9) 9018 (9.9)
25–29 19,288 (33.7) 7159 (31.5) 3686 (33.6) 30,133 (33.2)
30–34 21,928 (38.4) 9273 (40.8) 3990 (36.4) 35,191 (38.7)
35–39 8315 (14.5) 3856 (16.9) 1711 (15.6) 13,882 (15.3)
≥ 40 1047 (1.8) 493 (2.2) 263 (2.4) 1803 (2.0)
Maternal pre-pregnant Body Mass Index, n (%)
< 18.5 1663 (2.9) 660 (2.9) 319 (2.9) 2642 (2.9)
18.5–24.9 36,021 (63.0) 14,956 (65.7) 6655 (60.7) 57,632 (63.4)
25.0–29.9 12,003 (21.0) 4542 (20.0) 2443 (22.3) 18,988 (20.9)
30.0–34.9 3837 (6.7) 1402 (6.2) 842 (7.7) 6081 (6.7)
35.0–39.9 1091 (1.9) 354 (1.6) 232 (2.1) 1677 (1.8)
≥ 40 341 (0.6) 124 (0.5) 68 (0.6) 533 (0.6)
Missing 2203 (3.9) 717 (3.2) 413 (3.8) 3333 (3.7)
Parity, n (%)
Para 0 (first pregnancy) 25,428 (44.5) 10,897 (47.9) 4836 (44.1) 41,161 (45.3)
Para 1+ (second pregnancy or more) 31,731 (55.5) 11,858 (52.1) 6136 (55.9) 49,725 (54.7)
Maternal education, n (%)
≤ 12 years 18,849 (33.0) 6831 (30.0) 4177 (38.1) 29,857 (32.9)
13–16 years 22,042 (38.6) 9226 (40.5) 4018 (36.6) 35,286 (38.8)
≥17 years 12,725 (22.3) 5366 (23.6) 2097 (19.1) 20,188 (22.2)
Missing 3543 (6.2) 1332 (5.9) 680 (6.2) 5555 (6.1)
Smoking during pregnancy, n (%)
Never 45,831 (80.2) 18,208 (80.0) 8420 (76.7) 72,459 (79.7)
Occasionally 1421 (2.5) 567 (2.5) 374 (3.4) 2362 (2.6)
Daily 2848 (5.0) 968 (4.3) 821 (7.5) 4637 (5.1)
Missing 7059 (12.3) 3012 (13.2) 1357 (12.4) 11,428 (12.6)
Alcohol during pregnancy, n (%)
Never 42,203 (73.8) 16,731 (73.5) 7834 (71.4) 66,768 (73.5)
Less than once a week 5709 (10.0) 2512 (11.0) 1251 (11.4) 9472 (10.4)
Once a week 233 (0.4) 100 (0.4) 46 (0.4) 379 (0.4)
More than once a week 39 (0.1) 25 (0.1) 6 (0.1) 70 (0.1)
Missing 8975 (15.7) 3387 (14.9) 1835 (16.7) 14,197 (15.6)
Body Mass Index = weight (kg)/height2 (m)2
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polymer-based fillings placed during pregnancy and
birth outcomes. Michalowicz et al. found no significant
associations between adverse pregnancy outcomes and
periodontal treatment, the use of anaesthetic during
nonsurgical periodontal treatment, treatment including
temporary and permanent restorations, endodontic ther-
apy, and extractions [35]. These results are in agreement
with our findings. However, in the study of Michalowicz
et al., the type of restorative material was not specified.
Thus, the results are not directly comparable.
A limitation of the MoBa study is the low response
rate, with a possible self-selection of the healthiest
women. The MoBa has an underrepresentation of young
mothers (< 25 years). The participants have a higher
level of education and are more likely to be
non-smokers than the general population of pregnant
women in Norway [36].
However, self-selection to the cohort is not a validity
problem in studies of associations between exposure and
outcomes [36].
The MoBa study is based on questionnaires filled in by
the participating women. To achieve reliable answers from
all participants in this large cohort, an effort was made to
make the questions as easy and achievable as possible.
Thus, information about dental treatment is sparse.
Detailed information about the type and manufacturer of
the polymer-based filling material and size and number of
fillings placed, would be of interest. However, to obtain
accurate information about this, access to dental records
would be needed. In large epidemiological studies, like the
MoBa study, access to updated dental records would be
unfeasible. Accordingly, reliable knowledge about the
number and size of possible pre-existing composite resto-
rations is lacking. Since leakage of BPA from existing
polymer-based restorative materials is very low compared
with other sources [37], this information would most
likely be of minor importance.
The participants were asked if they had received
“white fillings” during pregnancy. In Norway, white
fillings would practically be the same as polymer-based
restorative fillings or so called polymer-based or
resin-based composites. However, the term “white fill-
ings” may include materials like resin-modified cements,
compomers and water-based glass ionomer cements
(GIC). In the period of this study, the vast majority of
Norwegian dentists used polymer-based filling materials
when restoring cavities in adults. Kopperud et al.
described management of occlusal caries in adults by
Norwegian dentists in 2009 and stated that polymer-based
composite was the preferred restorative material (91.9%)
[38]. In the same study the use of other filling materials
was reported to be less than 4%. This is in accordance
with another study examining treatment concept for
approximal caries in Norway [39]. In 2009 polymer-based
filling material was preferred by 94.9% of the responding
dentists. Preference for other filling materials was: 1.1%
compomer, 1.1% GIC, 0.5% resin-modified GIC and
1.8% a combination of resin composite and GIC [39].
In 1997, 2 years before recruitment started in MoBa,
Norwegian data showed that approximately 70% of
the tooth-coloured fillings placed in adults were
polymer-based [40].
Table 2 Birth outcomes by dental treatment during pregnancy (n = 90,886)
Did not consult a dentist Consulted a dentist,




Number of boys, n (%) 29,387 (51.4) 11,607 (51.0) 5582 (50.9) 46,576 (51.2)
Number of preterm births, n (%)
Very preterm births (≤ 32 weeks) 337 (0.6) 124 (0.5) 65 (0.6) 526 (0.6)
Late preterm births (33–36 weeks) 2150 (3.8) 884 (3.9) 454 (4.1) 3488 (3.8)
Mean birth weight (g)
Mean birth weight (SD) 3611 (546) 3603 (538) 3607 (549) 3608 (544)
Number of children with low birth weight, n (%)
Low birth weight (< 2500 g) 1465 (2.6) 576 (2.5) 290 (2.6) 2331 (2.6)
Small for gestational age (SGA) 10 percentile 3660 (6.4) 1475 (6.5) 726 (6.6) 5861 (6.5)
Small for gestational age (SGA) 2.5 percentile 793 (1.4) 293 (1.3) 145 (1,3) 1231 (1.4)
Number of children with high birth weight, n (%)
High birth weight children (> 4000 g) 12,515 (21.9) 4905 (21.6) 2390 (21.8) 19,810 (21.8)
Large for gestational age (LGA) 10 percentile 6633 (11.7) 2557 (11.3) 1285 (11.8) 10,475 (11.6)
Large for gestational age (LGA) 2.5 percentile 2110 (3.7) 809 (3.6) 418 (3.8) 3337 (3.7)
Number of children with malformation, n (%) 2697(4.7) 1108 (4.9) 519 (4.7) 4324 (4.8)
Number of stillbirths, n (%) 125 (0.2) 49 (0.2) 30 (0.3) 204 (0.2)
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Table 3 Crude and adjusted odds ratio (OR) and confidence interval (CI) for adverse birth outcomes related to dental treatment
during pregnancy. (Reference category: Women who did not consult a dentist, OR = 1)
Consulted a dentist, no white
fillings placed OR (95% CI)
Consulted a dentist, white
filling placed OR (95% CI)
Very preterm birth (≤ 32 weeks)
Girls Crude 0.96 (0.71–1.30) 0.91 (0.60–1.37)
Adjusted 0.94 (0.69–1.27) 0.88 (0.58–1.33)
Boys Crude 0.91 (0.69–1.21) 1.08 (0.76–1.53)
Adjusted 0.88 (0.67–1.17) 1.02 (0.72–1.45)
All Crude 0.92 (0.75–1.14) 1.01 (0.77–1.31)
Adjusted 0.90 (0.73–1.11) 0.97 (0.74–1.26)
Late preterm birth (33–36 weeks)
Girls Crude 1.00 (0.89–1.13) 1.05 (0.90–1.22)
Adjusted 1.00 (0.89–1.12) 1.03 (0.88–1.19)
Boys Crude 1.06 (0.95–1.18) 1.16*(1.01–1.34)
Adjusted 1.05 (0.94–1.18) 1.14 (0.99–1.31)
All Crude 1.03 (0.96–1.12) 1.10 (1.00–1.23)
Adjusted 1.03 (0.95–1.11) 1.08 (0.97–1.20)
Low birth weight (< 2500 g)
Girls Crude 1.01 (0.88–1.51) 1.03 (0.86–1.23)
Adjusted 0.98 (0.86–1.12) 0.99 (0.83–1.18)
Boys Crude 0.96 (0.84–1.11) 1.03 (0.86–1.24)
Adjusted 0.94 (0.82–1.09) 0.99 (0.83–1.19)
All Crude 0.99 (0.90–1.09) 1.03 (0.91–1.17)
Adjusted 0.96 (0.87–1.06) 0.99 (0.87–1.13)
Small for gestational age (SGA) 10 percentile
Girls Crude 1.07 (0.97–1.17) 1.14*(1.01–1.28)
Adjusted 1.03 (0.94–1.13) 1.10 (0.97–1.24)
Boys Crude 0.97 (0.89–1.05) 0.95 (0.85–1.07)
Adjusted 0.92 (0.84–1.00) 0.93 (0.83–1.04)
All Crude 1.01 (0.95–1.08) 1.04 (0.95–1.13)
Adjusted 0.97 (0.91–1.03) 1.00 (0.92–1.09)
Very small for gestational age (SGA) 2.5 percentile
Girls Crude 0.86 (0.71–1.06) 1.04 (0.81–1.34)
Adjusted 0.84 (0.68–1.03) 0.97 (0.75–1.25)
Boys Crude 0.98 (0.82–1.17) 0.88 (0.68–1.13)
Adjusted 0.93 (0.77–1.11) 0.84 (0.65–1.08)
All Crude 0.93 (0.81–1.06) 0.95 (0.80–1.14)
Adjusted 0.89 (0.77–1.02) 0.90 (0.75–1.08)
High birth weight (> 4000 g)
Girls Crude 0.99 (0.94–1.05) 0.98 (0.91–1.06)
Adjusted 1.03 (0.97–1.09) 0.98 (0.91–1.06)
Boys Crude 0.98 (0.93–1.03) 1.01 (0.94–1.07)
Adjusted 1.01 (0.96–1.06) 1.00 (0.93–1.07)
All Crude 0.98 (0.94–1.02) 0.99 (0.95–1.04)
Adjusted 1.01 (0.98–1.05) 0.99 (0.94–1.04)
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The participants answered questions regarding
dental treatment during the first 30 weeks of preg-
nancy but were not asked to specify in which week of
pregnancy they visited the dentist. Hence, a limitation
is that we could not study if treatment with
polymer-based filling materials could be a factor of
importance at specific time windows during preg-
nancy. The severity of the effects of prenatal exposure
to toxic agents appears to be influenced by the degree
and timing of the exposure during gestation [41].
Some teratogens cause damage only during specific
days or weeks early in pregnancy, when a particular
part of the body is formed [41]. A well-known
example is the thalidomide-tragedy in the late 1950s
and the early 1960s, where the medication taken
during days 20–36 after fertilization resulted in
serious malformations of the foetus [42, 43].
Some women with the need for dental treatment do
not seek or do not receive dental care during preg-
nancy [44]. This may, in part, be due to their
concerns about the potential risk to the foetus, as
well as dentists and other health care providers’ atti-
tudes and beliefs about the safety of dental treatment
during pregnancy [44].
The findings from the present study, including more
than 90,000 pregnancies, are reassuring. However, taken
the limitations of a prospective cohort study into
account, these findings could be corroborated in case
Table 3 Crude and adjusted odds ratio (OR) and confidence interval (CI) for adverse birth outcomes related to dental treatment
during pregnancy. (Reference category: Women who did not consult a dentist, OR = 1) (Continued)
Consulted a dentist, no white
fillings placed OR (95% CI)
Consulted a dentist, white
filling placed OR (95% CI)
Large for gestational age (LGA) 10 percentile
Girls Crude 0.96 (0.90–1.02) 0.99 (0.91–1.08)
Adjusted 1.00 (0.93–1.07) 0.98 (0.90–1.08)
Boys Crude 0.97 (0.90–1.04) 1.03 (0.94–1.13)
Adjusted 1.01 (0.94–1.08) 1.01 (0.93–1.11)
All Crude 0.96 (0.92–1.01) 1.01 (0.95–1.08)
Adjusted 1.01 (0.96–1.06) 1.00 (0.94–1.06)
Large for gestational age (LGA) 2.5 percentile
Girls Crude 0.97 (0.87–1.09) 1.01 (0.87–1.17)
Adjusted 1.02 (0.91–1.15) 0.99 (0.86–1.15)
Boys Crude 0.95 (0.84–1.07) 1.06 (0.90–1.24)
Adjusted 0.98 (0.87–1.11) 1.03 (0.88–1.20)
All Crude 0.96 (0.88–1.04) 1.03 (0.93–1.15)
Adjusted 1.00 (0.92–1.09) 1.01 (0.91–1.12)
Malformation
Girls Crude 1.02 (0.92–1.14) 0.99 (0.86–1.15)
Adjusted 1.00 (0.90–1.12) 1.00 (0.86–1.15)
Boys Crude 1.05 (0.95–1.15) 1.01 (0.89–1.15)
Adjusted 1.03 (0.94–1.14) 1.00 (0.88–1.14)
All Crude 1.03 (0.96–1.11) 1.00 (0.91–1.10)
Adjusted 1.02 (0.95–1.09) 1.00 (0.91–1.10)
Stillbirth
Girls Crude 0.96 (0.59–1.55) 1.20 (0.67–2.15)
Adjusted 0.92 (0.57–1.50) 1.16 (0.64-2.07)
Boys Crude 0.97 (0.61–1.54) 1.30 (0.75–2.24)
Adjusted 0.95 (0.60–1.51) 1.22 (0.70–2.11)
All Crude 0.98 (0.71–1.37) 1.25 (0.84–1.86)
Adjusted 0.96 (0.69–1.33) 1.18 (0.79–1.76)
The OR was adjusted for mothers age (≤19, 20–24, 25–29, 30–34, 35–39, 40+), parity (0, 1 or more previous viable pregnancies), education (≤ 12 years, 13–16 years,
≥ 17 years), pre-pregnancy body mass index (< 18.5, 18.5–24.9, 25.0–29.9, 30.0–34.9, 35.0–39.9, ≥ 40), smoking (never, occasionally, daily) and alcohol consumption
during pregnancy (never, less than once a week, once a week, more than once a week). *p < 0.05
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control studies. Thus, access to dental records and
thereby accurate and detailed information regarding
dental treatment could be possible to obtain.
Conclusion
In this study, women who had white fillings placed
during pregnancy had no increased risk for adverse birth
outcomes compared with women who did not consult a
dentist during pregnancy. Thus, our findings do not sup-
port the hypothesis of an association between placement
of polymer-based fillings during pregnancy and adverse
birth outcomes.
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Analysis of bisphenol A in saliva 
Bisphenol A (BPA) and D16-BPA, were obtained from Sigma-Aldrich Inc. (St. Louis, 
MO, USA). Acetonitrile, ammonium acetate and methanol were from Merck 
(Darmstadt, Germany). Water was from a Milli-Q Integral 5 system (Millipore, 
Billerica, MA, USA). β-Glucuronidase (Escherichia coli K12) was obtained from 
Roche Diagnostics with a specific activity of ~80 units/mg protein (Glucuronidase at 
25°C, or 140 U/mg at 37 °C, at pH 7 with 4-nitrophenyl-β-D-glucuronide as substrate. 
(Mannheim, Germany). 
Stock solutions were prepared by dissolving accurately weighed amounts of BPA in 
methanol. Standard solutions were prepared by further dilution of the stock solutions 
in methanol. Serum was used for the calibration standards and for quality control (QC) 
samples and was obtained from healthy volunteers at our laboratory. The levels were 
quantified and samples with low amount of BPA were selected for the calibration 
standards. Calibration standards were prepared by adding 25 µl standard solution to 
serum. Two quality control serum samples were prepared by additions of small 
amounts of BPA into pooled samples. 
The samples were prepared in 96-well plates with 2 ml flat bottom glass vials (Biotech 
solutions, Vineland, NJ, USA). For the analysis of total BPA in the samples, aliquots 
of 100 µl saliva were added with 10 µl glucuronidase, 10 µl 1M ammonium acetate 
buffer at pH 6.5. The samples were digested at 37°C for 90 min. Then 25 µl of 
methanol containing D16-BPA as internal standard and an additional 25 µl methanol 
was added, thereafter the proteins were precipitated with 200 µl acetonitrile followed 
by vigorous shaking for 30 min. For the calibration standards, aliquots of 100 µl serum 
were used and treated as above, but standards were added 25 µl methanol. The 
samples were thereafter centrifuged at 2600g for 10 min. The supernatant (0.2 ml) was 
transferred to a new 96-well plate with 0.5 ml conical glass vials (MicroLiter 
Analytical Supplies, Inc., Suwanee, GA, USA) for analysis. Samples analyzed for free 
BPA in saliva was determined as above but digestion using glucuronidase was 
omitted. Concentration of conjugated BPA was estimated by the difference between 
total and free BPA. 
Quantitative analysis was conducted using a triple quadrupole linear ion trap mass 
spectrometry (QTRAP 5500; AB Sciex, Foster City, CA, USA) coupled to a liquid 
chromatography system (UFLCXR, Shimadzu Corporation, Kyoto, Japan; 
LC/MS/MS). Air was used as nebulizer and auxiliary gas. Pure nitrogen was used as 
curtain gas and collision gas. The temperature of the auxiliary gas was set at 630 °C 
and the ion spray voltage was -4500 V. The MS analyzes were carried out using 
selected reaction monitoring (SRM) in negative ion mode. BPA was analyzed using 
the transitions m/z 227-212 as quantifier ion, m/z 227-133 as qualifier ion and m/z 
241-142 was used for the internal standard.
For the analysis of BPA a C18 column (2.1 mm i.d. x 50 mm, Genesis Lightn; Grace, 
Deerfield, IL, USA) was used prior to the injector to filter the mobile phases from 
contaminating BPA. Aliquots of 3 µl of the samples were injected on a C18 column 
(1.5 µm, 2.0 mm i.d. x 100 mm VisionHT; Grace, Deerfield, IL, USA). The mobile 
phases were A: water and B: methanol. The mobile phase was kept at 15% B for 1 min 
after injection. A gradient was then applied in 4 min to 95% B where it was kept for 
2.6 min. The column was then conditioned at 15% B for 2 min. A diverter valve was 
used and the column effluent was diverted to the MS between 6.0 and 7.5 min. The 
flow rate was 0.25 ml/min and the column was maintained at 60 °C.  
Concentrations were determined by peak area ratios between the analytes and the IS. 
The levels of BPA in the pooled serum used for preparation of standards were 
quantified in each batch and the calibration standards were corrected for the 
concentration found in this pooled sample. Also, all values were corrected for the 
mean of chemical blanks, run within each batch. 
The LOD was calculated as three times the standard deviation of the ratio between the 
peak area at the analyte retention time and the peak area of IS, divided by the slope of 
the calibration line. The LOD was determined to 0.1 ng/ml. 
In all analytical batches there were two different in-house prepared quality control 
(QC) samples and chemical blanks analyzed. The samples were prepared and analyzed 
in duplicates and the mean of the two concentrations were used. 
Between-day precision was estimated from the in house prepared QC samples 
analyzed several times within an analysis batch data from a different project where 76 
batches were analyzed are included. The CV of the two quality control sample was at 
2.6 ng/ml 14% and at LOD at 0.1ng/ml 42%. 
The within run precision were determined in spiked serum samples (n=10) at three 
different levels. The CVs were at 13 ng/ml 2.8%, at 7 ng/ml 3.4% and at 2 ng/ml 4%. 
The laboratory in Lund performing the analyzes is a European reference laboratory for 
BPA in urine (www.eu-hbm.info/democophes) and a reference laboratory for BPA in 
urine in the Erlangen Round Robin inter-laboratory control program. 
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Spørreskjema 1  
 




Dato for utfylling:……………           Initialer/journalnr. i prosjekt:…………………… 
 
Fødselsår: ……………………… Alder:………………….. 
 
Kjønn: Kvinne                   Mann  
 
Utdannelse:                                          Yrke/arbeidssituasjon: …………………. 
 
Sykdommer: Ingen          Hvilke: ………………………………….. 
 
Allergier: Ingen           Hvilke:……………………………………... 
 
Medikamenter/Naturpreparater: Ingen:          Hvilke:………………………………… 
 
Kassajobb: Nei           Ja                 Daglig             Ukentlig            Månedlig  
 
Nytelsesmidler/alkoholvaner: 
Røyk  Nei   Daglig    Ukentlig   Månedlig 
Snus  Nei   Daglig    Ukentlig    Månedlig 
Alkohol Nei   Daglig    Ukentlig    Månedlig 
Andre  Nei   Daglig    Ukentlig   Månedlig 
 
Bruk av tyggegummi daglig: Nei  Ja 
 
Bruk av tannkrem daglig: Nei  Ja  Hvilken:…………………   
                                                    Benyttet i dag:  Nei  Ja 
 
Munnskyllemiddel: Nei   Ja  Hvilket:………........  
                                          Daglig  Ukentlig  Månedlig    
                                          Benyttet i dag: Nei  Ja 
 
Inntak av hermetiske fødeemner:  
Siste 24 timer: Nei   Ja     Hvilke: ………………………..                                
Siste uken:  Nei   Ja     Hvilke: ……………………….   
                              
Inntak mikrobølgevarmet mat, varmet i plastemballasje: 
Siste 24 timer: Nei     Ja     Spesifiser………………………………..                                   
Siste uken:      Nei     Ja      Spesifiser……………………………….                                   
 
Har du spist frokost i dag? Nei  Ja     Hvilke fødeemner: …………………… 











Dato for utfylling:……………           Initialer/journalnr. i prosjekt:…………………… 
 
 
Inntak av hermetiske fødeemner:  
Siste 24 timer: Nei        Ja     Hvilke:……………………….. ……………                               
                              
Inntak mikrobølgevarmet mat, varmet i plastemballasje: 
Siste 24 timer: Nei        Ja      Spesifiser: ………………………………...                              
 
Har du pusset tenner i dag?  Nei  Ja     Hvilken tannkrem…………………… 
 
Har du brukt munnskyllemiddel i dag? Nei  Ja     Hvilket middel …………… 
 
 
Har du spist frokost i dag? Nei  Ja     Hvilke fødeemner: …………………… 
 
 










Dato for utfylling:……………           Initialer/journalnr. i prosjekt:…………………… 
 
 
Inntak av hermetiske fødeemner:  
Siste 24 timer: Nei   Ja          Hvilke:………………………..                                
Siste uken:      Nei   Ja         Hvilke: ……………………….   
                              
Inntak mikrobølgevarmet mat, varmet i plastemballasje: 
Siste 24 timer: Nei     Ja       Spesifiser:…………………………………                                
Siste uken:      Nei     Ja       Spesifiser:……………………. …………...                                
 
Har du pusset tenner i dag?  Nei  Ja     Hvilken tannkrem…………………… 
 
Har du brukt munnskyllemiddel i dag? Nei  Ja     Hvilket middel …………… 
 








Analysis of bisphenol A 
Bisphenol A (BPA) and D16-BPA were obtained from Sigma-Aldrich Inc. (St. Louis, 
Missouri, USA). Acetonitrile (AcN) and ammonium acetate were from Merck 
(Darmstadt, Germany). Water was from a Milli-Q Integral 5 system (Millipore, 
Billerica, Massachusetts, USA). Serum (Fetal Bovine Serum) was from Gibco Thermo 
Fisher Scientific (Waltham, Massachusetts, USA). β-Glucuronidase (Escherichia coli 
K12) was obtained from Roche Diagnostics (Mannheim, Germany). 
Preparation of standard samples and control samples (quality control) 
Stock solutions were prepared by dissolving accurately weighed amounts of BPA in 
50% AcN. Standard solutions were prepared by further dilution of the stock solutions 
in 50% AcN. Serum was used for the calibration standards for the saliva analysis and 
urine (obtained from healthy volunteers at our laboratory) for the urine analysis  
Calibration standards were prepared by adding 25 μl standard solution each to serum 
and urine. Two control samples were used for quality control (QC). Samples were 
prepared by additions of small amounts of BPA into pooled urine samples.  
Preparation of saliva samples 
The samples were prepared in 96-well plates with 2-ml flat bottom glass vials (Biotech 
solutions, Vineland, New Jersey, USA). For the analysis of total BPA in the samples, 
aliquots of 100 μl of saliva were added with 10 μl glucuronidase and 10 μl of 1M 
ammonium acetate buffer at pH 6.5. The samples were digested at 37°C for 90 min. 
Then, 25 μl of 50% AcN containing D16-BPA as the internal standard and an 
additional 25 μl of 50% AcN was added. Thereafter, the proteins were precipitated 
with 200 μl acetonitrile followed by vigorous shaking for 30 min. For the calibration 
standards, aliquots of 100 μl of serum were used and treated as above, but standards 
were added in 25 μl of AcN. The samples were thereafter centrifuged at 2600 ×g for 
10 min. The supernatant (0.2 ml) was transferred to a new 96-well plate with 0.5-ml 
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conical glass vials (MicroLiter Analytical Supplies, Inc., Suwanee, Georgia, USA) for 
analysis and centrifuged again at 3000 ×g for 10 min before analysis.  
Preparation of urine samples 
The samples were prepared in 96-well plates with 1-ml glass inserts (1-ml SQW 
Micro-Inserts, La-Pha-Pack, Langerwehe, Germany). For the analysis of total BPA in 
the samples, aliquots of 200 μl of urine were added with 10 μl of glucuronidase and 
100 μl of 1M ammonium acetate buffer at pH 6.5. The samples were digested at 37°C 
for 30 min. Then, 25 μl of 50% AcN containing D16-BPA as the internal standard and 
an additional 25 μl of 50% AcN was added. For the calibration standards, aliquots of 
200 μl of urine were used and treated as above, but standards were added in 25 μl of 
50% AcN. The samples were thereafter centrifuged at 3000 ×g for 10 min.  
Samples analyzed for free BPA in saliva were determined as above but digestion using 
glucuronidase was omitted. The concentration of conjugated BPA was estimated by 
the difference between total and free BPA. 
Quantitative analysis 
Quantitative analysis was conducted using triple quadrupole linear ion trap mass 
spectrometry (QTRAP 5500; AB Sciex, Foster City, California, USA) coupled to a 
liquid chromatography system (UFLCXR, Shimadzu Corporation, Kyoto, Japan; 
LC/MS/MS). Pure Nitrogen was used as the nebulizer, auxiliary gas, curtain gas, and 
collision gas. The temperature of the auxiliary gas was set at 630°C and the ion spray 
voltage was −4500 V. The MS analyses were carried out using selected reaction 
monitoring (SRM) in negative ion mode. BPA was analyzed using the transitions m/z 
227-212 as the quantifier ion, m/z 227-133 as the qualifier ion, and m/z 241-142 was 
used for the internal standard. 
In the LC system, a C18 column (4 µm, 2.1-mm i.d. x 50-mm, Genesis Lightning; 
Grace, Hichrom, Reading, United Kingdom) was used prior to the injector to filter the 
mobile phases from contaminating BPA. Aliquots of 5 μl of the samples were injected 
on a C18 column (same as above). The mobile phases were A: water and B: methanol, 
both containing 0.08% NH3. The mobile phase was maintained at 5% B for 0.2 min 
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after injection. A gradient was then applied in 7 min to 70% B and another 0.5-min 
increase of B to 95%. The column was then conditioned at 5% B for 1.5 min. A 
diverter valve was used and the column effluent was diverted to the MS between 4 and 
7 min. The flow rate was 0.6 ml/min and the column was maintained at 45°C. 
Concentrations were determined by peak area ratios between the analytes and the 
internal standard (IS). In addition, all values were corrected for the mean of the 
chemical blanks, which were run within each batch. 
The limit of detection (LOD) was calculated as three times the standard deviation of 
the ratio between the peak area in the chemical blank samples at the analyte retention 
time and the peak area of IS, divided by the slope of the calibration line. The LOD was 
determined to be 0.1 ng/ml for both saliva/serum and urine analysis. 
In all analytical batches there were two different in-house prepared QC samples and 
chemical blanks analyzed. The samples were prepared and analyzed in duplicates and 
the mean of the two concentrations was used. 
Between-run precision was estimated from the above QC samples analyzed in 76 
batches of urine samples. The CV of the two QC samples was at 2.6 ng/ml 14% and at 
LOD at 0.1 ng/ml 42%. 
The within-run precision was determined in spiked serum samples (n=10) at three 
levels. The CVs were at 13 ng/ml 2.8%, at 7 ng/ml 3.4% and at 2 ng/ml 4%. The 
laboratory in Lund performing the analyses is a European reference laboratory for 
BPA in urine (www.eu-hbm.info/democophes) and a reference laboratory for BPA in 
urine in the Erlangen Round Robin inter-laboratory control program. 
Qualitative analysis 
Because, in the HPLC-MSMS run of the saliva samples, there was a small shift in the 
retention time between the BPA peak in the standard samples and the BPA peak in the 
saliva samples, a more thorough investigation was made to be able to confirm that the 
peaks in the saliva samples originate from BPA. The samples were also analyzed on a 
quadropol time of flight mass spectrometer (QTOF; Triple TOF 5600; AB Sciex, 
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Foster City, CA, USA) coupled to a liquid chromatography system (UFLCXR, 
Shimadzu Corporation, Kyoto, Japan). 
The columns and mobile phases including the settings were the same as for 
quantitative analysis. The mobile phase was kept at 5% B for 0.5 min after injection. A 
gradient was then applied in 3.5 min to 95% B and was maintained for 1 min. The 
column was then conditioned at 5% B for 1.5 min. The column effluent was diverted 
to the MS between 3.0 and 4.7 min.  
The temperature of the auxiliary gas on the MS was 600°C and the ion spray voltage 
was −4500 V. The MS analysis was carried out using product ion scan in negative ion 
mode. For accurate mass determination, BPA was analyzed using the precursor ions 
m/z 227.1 for BPA, and m/z 241.1 was used for the BPA-D16 internal standard.  
The QTOF spectra of the chromatographic BPA peak from the standard were 
compared with the QTOF spectra of the chromatographic BPA peak from the saliva 
samples. The spectra found in the standard sample were comparable to the peak found 
in saliva, thus suggesting that the peak in the saliva samples is an isomer of BPA and 
this causes a small shift in the retention time.  
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